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21. INTRODUCTION
In pharmacology, bioavailability (BA) is a subcategory of absorption and is the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation, which is one of the 
principal pharmacokinetic properties of drug. By definition, when a medication is administered 
intravenously, its bioavailability is 100%. However, when a medication is administered via other 
routes (such as oral), its bioavailability generally decreases (due to incomplete absorption and 
first-pass metabolism) or may vary from patient to patient. Bioavailability is one of the essential 
tools in pharmacokinetics as bioavailability must be considered when calculating dosages for 
non-intravenous routes of administration. 
Bioequivalence (BE) study is a comparative study of bioavailability among drug products that 
contain the same active agents. Bioavailability and bioequivalence of drug products and drug 
product selection have emerged as critical issues in pharmacy and medicine during the last three 
decades. Concern about lowering health costs resulted in tremendous written increase in the use 
of generic drug products. Currently about one half of all prescriptions written are for drugs that 
can be substituted with a generic drug. 
This circumstantial growth of generic pharmaceutical industry and the abundance of 
multisource products have prompted some questions among health professionals and 
scientists regarding the therapeutic equivalency of these products. Inherent in the currently 
accepted guidelines for product substitution is the assumption that a generic drug 
considered to be equivalent to a innovator drug would elicit the same clinical effect. 
Numerous papers in the literature indicate that there is concern that the current standards 
for approval of generic drugs may not always ensure therapeutic equivalence. The 
availability of different formulations of the same drug substance given at the same strength 
and in the same dosage form poses a special challenge to health care professionals. 
1.1 Bioavailability
 1
Bioavailability is defined as: ―The rate and extent to which the active ingredient or active 
moiety is absorbed from a drug product and becomes available at the systemic circulation.‖
3Bioavailability: 
• It is the fraction of unchanged drug reaching the systemic circulation following
administration by any route.
• To exert an optimal therapeutic action, an active moiety should be delivered to its site of
action in an effective concentration for the desired period.
• The influence of route of administration on drug‘s bioavailability is:
Parenteral > oral > rectal > topical
• Intravenous injection of a drug results in 100% bioavailability as the absorption process
is bypassed. Even in such cases, the dose available to the patient called as the
bioavailable dose is often less than the administered dose.
• Estimation of bioavailability is a means of predicting the clinical efficacy of a drug.
• Bioavailability testing measuring the rate and extent of drug absorption is a way to
obtain evidence of the therapeutic utility of a drug product.
 Fraction of administered dose that enters the systemic circulation 
Bioavailable dose 
F = 
Administered dose  
It ranges from 0 to 1. Bioavailability is normally expressed as %. 
1.1.1 Types of Bioavailability
Absolute bioavailability (F) 
• When systemic availability of drug administered orally is determined in comparison to
it‘s intravenous administration ie is called absolute bioavailability.
• It‘s determination is used to characterize a drug‘s inherent absorption properties from the
extra vascular site.
[AUC]ev/(Dose)ev 
Absolute bioavailability = 
[AUC]iv/(Dose)iv 
(ev- extra vascular, iv- intravenous and AUC – Area Under the Curve) 
4Relative Bioavailability (Fr)
• When systemic availability of drug after oral administration is compared with that of an
oral standard of same drug (such as an aqueous or non-aqueous solution or suspension), it
is referred as relative bioavailability.
• It is used to characterize absorption of drug from its formulation.
[AUC]test /(Dose)test 
Relative Bioavailability = 
 [AUC]std/(Dose)std 
• Before the therapeutic effect of an orally administered drug can be realized, the drug
must be absorbed.
Supra bioavailability 
Supra bioavailability is a term used when a test product displays larger bioavailability than the 
reference product. Such formulations are usually not to be accepted as therapeutically equivalent 
to the existing reference product. 
1.1.2 General Objectives of Bioavailability Studies
2
Bioavailability studies are important in the determination of influence of excipients, patient 
related factors, and possible interaction with other drugs on the efficiency of absorption.
•
Development of new formulations of the existing drugs e.g. innovator vs generic.
Bioequivalence study looking for similarity of F and ka values between the products.
• To compare one type of dosage form with another e.g. tablet versus intravenous dosage
form or regular tablet with sustained release tablet. Bioavailability study where ka and F
are to be determined. Changes in ka may be intentional (slow release) whereas F values
should be similar.
Factors Influencing Bioavailability 
The absolute bioavailability of a drug when administered by an extra vascular route is usually 
less than one (i.e. F<1). Various physiological factors reduce the availability of drugs prior to 
their entry into the systemic circulation.8
5Such factors may include but are not limited to: 
• Physical properties of the drug (hydrophobicity, pKa, and solubility)
• The drug formulation (immediate release, excipients used, manufacturing methods,
modified release - delayed release, extended release, and sustained release, etc.) 
• If the drug is administered in a fed or fasted state
• Gastric emptying rate
• Circadian differences
• Enzyme induction/inhibition by other drugs/foods.
• Disease state e.g. Hepatic insufficiency, poor renal function
Each of these factors may vary from patient to patient (inter-individual variation) and indeed in 
the same patient over time (intra-individual variation). Whether a drug is taken with or without 
food will affect absorption. Other drugs taken concurrently may alter absorption and first-pass 
metabolism. Intestinal motility alters the dissolution of the drug and may affect the degree of 
chemical degradation of the drug by intestinal micro flora. Disease states affecting liver 
metabolism or gastrointestinal function will also have an effect. 
Absolute bioavailability compares the bioavailability (estimated as area under the curve, or 
AUC) of the active drug in systemic circulation following non-intravenous administration (i.e., 
after oral, rectal, transdermal, subcutaneous administration) with the bioavailability of the same 
drug following intravenous administration.
Relative bioavailability is extremely sensitive to drug formulation. Relative bioavailability is one 
of the measures used to assess bioequivalence between two drug products as it is the Test/
Reference ratio of AUC. The maximum concentration of drug in plasma or serum (Cmax) is also 
usually used to assess the bioequivalence. 
If the size of the dose to be administered is same, then bioavailability of a drug from its 
dosage form depends upon three major factors:
 Pharmaceutical factors related to physiochemical properties of the drug and
characteristics of dosage form.
 Patient related factors.
 Route of administration.
61.1.3 Methods for assessing bioavailability
2
The methods useful in quantitative evaluation can be divided into 2 categories 
I. Pharmacokinetic methods (indirect method)
These are very widely used and based on the assumption that the pharmacokinetic profile 
reflects the therapeutic effectiveness of a drug. Thus, these are indirect methods.  
There are two methods in this type: 
1. Plasma level-time studies
2. Urinary excretion studies
II. Pharmacodynamic methods (direct method)
These methods are complementary to pharmacokinetic approaches and involve direct 
measurement of drug effect on pathophysiological process as a function of time. 
 The two pharmacodynamic methods are: 
1. Acute pharmacological response
2. Therapeutic response
Pharmacokinetic Parameters
3
Cmax: Maximum measured plasma concentration after the administration of single dose of the
drug expressed in terms of μg/mL or ng/mL. 
AUC0-t: The area under the plasma concentration versus time curve from time zero to the last 
time point with measurable concentration calculated by the linear trapezoidal method. 
AUC₀-∞: The area under the plasma concentration versus time curve from time zero to time 
infinity. AUC0-∞ is calculated as the sum of the AUC0-t plus the ratio of the last measurable 
concentration to the elimination rate constant.  
Tmax: Time of maximum measured plasma concentration. If the maximum value occurs at more 
than one point, Tmax is defined as the first point with this value in each period, which is an 
indication of the rate of absorption expressed in terms of hours or minutes. 
7Kel: Apparent first order elimination or terminal rate constant calculated from a semi-log plot of 
the plasma concentration versus time curve.  
T1/2: Apparent first-order terminal elimination half-life will be calculated as 0.0693/Kel. The 
various pharmacodynamic parameters, which influence the above mentioned 
pharmacokinetic parameters are: 
Minimum Effective Concentration (MEC) 
3
It is defined as the minimum concentration of drug in plasma required to produce the therapeutic 
effect. It reflects the minimum concentration of the drug at the receptor site to elicit the desired 
pharmacologic response. The concentration of drug below MEC is said to be in the sub 
therapeutic level. 
Maximum Safe Concentration (MSC)
3
Also called as minimum toxic concentration, it is the concentration of the drug in plasma above 
which adverse or unwanted effects are precipitated. Concentration of drug above MSC is said to 
be in the toxic level. 
Onset of Action 
The interval between the beginning of pharmacologic response and drug administration is called 
as onset of action. It occurs when the plasma drug concentration exceeds the required MEC. 
Onset Time 
It is the time required for the drug to start producing pharmacologic response. It 
corresponds to the time of plasma concentration to reach MEC after administration of drug. 
Duration of Action 
The time period for which the plasma concentration of drug remains above the MEC level 
is called as duration of drug action. 
8Therapeutic Range
The drug concentration between MEC and MSC represents the therapeutic range.
Figure 1: Pharmacokinetic parameters. 
Bioavailability is needed for 
 Drugs having low therapeutic index e.g. cardiac glycosides, quinidine, phenytoin etc.
 The peak levels of drugs are required to find the effect of drugs e.g. phenytoin,
phenobarbitone, primidone, sodium valproate, anti-hypertensives, antidiabetics and
antibiotics.
 Drugs that are absorbed by an active transport e.g. amino acid analogues, purine analogues
etc.
 Drugs which are disintegrated in the alimentary canal and liver e.g. chlorpromazine etc., or
those which under go first pass metabolism.
 Formulations that give sustained release of drug with smaller disintegration time than
dissolution rate and drugs used as replacement therapy also warrant bioavailability testing. In
addition, any new formulation has to be tested for its bioavailability profile.
91.2 Bioequivalence (BE) 
3
Chemical equivalents, which when administered to the same individuals in the same dosage 
regimen will result in comparable bioavailability. Bioequivalence gained increasing attention 
during the last 40 years after it became evident that marketed products having the same amounts 
of the drug may exhibit marked differences in their therapeutic responses. When drug products 
are administered to individuals, the investigator inevitably finds differences in one or more of the 
variables measured. These differences are due partly to factors related to dosage form and partly 
to biological factors unique to each individual since each person has his own characteristics for 
absorption, metabolism, and excretion of each drug. Through appropriate use of statistical 
procedures, it is possible to identify the variations that result from differences among individuals 
and thus to isolate those that result from differences in the bioavailability of the drug products. 
Generally, these differences were well correlated to dissimilar drug plasma levels caused mainly 
by impaired absorption. Now a considerable body of evidence has accumulated indicating that 
drug response is better correlated with the plasma concentration or with the amount of drug in 
the body than with the dose administered. Consequently, on the basis of simple pharmacokinetic 
concepts and parameters, bioavailability and bioequivalence studies have been established as 
acceptable surrogates for expensive complicated and lengthy clinical trials and are used 
extensively worldwide to establish and ensure consistent quality and a reliable therapeutically 
effective performance of marketed dosage forms. 
 Bioequivalence studies compare both the rate and extent of absorption of various multisource 
drug formulations with the innovator (reference) product on the basis that if two formulations 
exhibit similar drug concentration-time profiles in the blood/plasma, they should exhibit similar 
therapeutic effects.  
Three situations have thus been defined in which bioequivalence studies are required: 
 When the proposed marketed dosage form is different from that used in pivotal clinical
trials.
 When significant changes are made during the manufacturing of the marketed
formulation.
 When a new generic formulation is tested against the innovator‘s marketed product.
10
Comparative evidence may require not only studies in a fasting condition but following a 
specified meal. The latter permit drug formulations to be evaluated under "stressed 
conditions". If it is shown that competitive products are bioequivalent under both fasting 
and fed conditions, there is greater confidence that they are therapeutically equivalent 
when used in patients. Bio-equivalent simply means a drug or dosage form of a drug or 
supplement is equivalent to a reference brand or dosage form of the same drug or 
supplement in terms of various bioavailability parameters measured via in-vivo testing in 
human subject. 
1.2.1 Factors Influencing Bioequivalence
4
 Delayed gastric emptying
 Stimulation of bile flow
 Change in gastrointestinal pH
 Increase splanchnic blood flow
 Change in luminal metabolism of a drug substance
 Physical or chemical interaction with a dosage form or a drug substance
 Food can change the BA of a drug and hence can influence the BE between test and
reference products
1.2.2 Types of bioequivalence
4
Chemical equivalence 
It indicates that two or more drug products that contain the same chemical substance as an 
active ingredient in the same amount. 
Pharmaceutical equivalence 
It is a relative term, which denotes that the drug substance in two or more forms is identical in 
strength, quality, purity, content uniformity, disintegration and dissolution characteristics. They 
may however differ in containing different excipients. 
11
Therapeutic equivalence 
It indicates that two or more drug products that contain the same therapeutically active 
ingredient elicits identical pharmacological effects and can control the disease to the same extent. 
Types of bioequivalence studies 
o In vivo studies
o In vitro studies
In Vivo Studies 
The following points are used in assessing the need for in vivo studies: 
 Oral immediate release products with systemic action.
 Indicated for serious conditions requiring assured response.
 Narrow therapeutic margin.
 Pharmacokinetics complicated by absorption lesser than 70% or non linear kinetics,
presystemic elimination greater than 70%.
 Unfavorable physiochemical properties like low solubility, metastable conditions,
instability,etc.
 Non- oral immediate release products.
 Modified release products with systemic action.
In Vitro Studies 
If none of the above criteria is applicable, comparative in vitro dissolution studies will 
suffice. In vitro studies are conducted in cases where, 
 The product is intended for topical administration (Cream, ointment, and gel) for local
effect.
 The product is for oral administration but not intended to be absorbed (antacid or
opaque medium).
 The product is administered by inhalation as a gas or vapour.
12
1.3 General Concepts of Design and Conduct of Studies
5
The design and conduct of the study should follow the Good Clinical Practice including 
reference to an Ethics Committee.
As recommended by the US FDA (1992), in most bioequivalence trials, a test formulation is 
compared with the standard/innovator reference formulation in a group of normal healthy 
subjects (18-45 year) each of whom receive both the treatments alternately in a crossover fashion 
(two-period, two-treatment crossover design) with the two phases of treatment separated by a 
washout period of generally a week duration but may be longer (a minimum time equivalent to 5 
half-lives) if the elimination half-life of the drug is very long. The treatment is assigned to each 
subject randomly but an equal number of subjects receive each treatment in each phase. Thus in 
case of two treatments standard (S) and test (T), one group gets the treatment in the order S and 
T and the second group in the reverse order T and S. This is done to avoid the occurrence of 
possible sequence or period effects. A similar allocation is done in case of a three-treatment 
crossover design (three-period, three-treatment crossover design). 
For several drugs, a great inter-subject variability in clearance is observed. The intra-subject 
coefficient of variation (approximately 15%) is usually substantially smaller than that between 
subjects (approximately 30%) and therefore, crossover designs are generally recommended for 
bioequivalence studies. 
The primary advantage of the crossover design is that since the treatments are compared on the 
same subject, the inter subject variability does not contribute to the error variability. If the drug 
under investigation and/or its metabolites has an extremely long half-life, a parallel group design 
may be indicated. In a parallel group design, subjects are divided randomly into groups and each 
group receive one treatment only. Thus each subject receives only one treatment. In a parallel 
design, although one does not have to worry about sequence period or carry over effects or 
dropouts during the study. The inter-subject variability being very high, the sensitivity of the test 
is considerably reduced thus requiring a larger number of subjects compared to a crossover 
design to attain the same sensitivity. 
13
Inherent in both the crossover and parallel designs are the three fundamental statistical 
concepts of study design namely  
 Randomization
 Replication and Error control.
Randomization
It implies allocation of treatments to the subjects without selection bias. Consequently
randomization is essential to determine an unbiased estimate of the treatment effects. 
Replication
It implies that a treatment is applied to more than one experimental unit (subject) to
obtain more reliable estimates than is possible from a single observation and hence provides a 
more precise measurement of treatment effects. The number of replicates (sample size) required 
will depend upon the degree of differences to be detected and inherent variability of the data. 
Replication is used concomitantly with Error control to reduce the experimental error or error 
variability.  
More commonly used replicated crossover designs to compare two formulations are: 
• Four-sequence and two-period design (Balaam‘s design)
• Two-sequence and four-period design
• Four-sequence and four-period design
• Two-sequence and three-period design
• Crossover design for three medications (Williams‘s design)
• Crossover design for four medications (Williams‘s design)
• Crossover design for two medications (t - test; r - reference)
2x2 Crossover design
6
This is a conventional not-replicated design with two formulations, two periods, two 
sequences that may be represented as follows: 
14
Each individual is randomly assigned to RT or TR sequence in two dosage periods. That is, 
individuals assigned to RT (TR) sequence receive formulation R in the first dosage period and 
formulation T in the second dosage period. Randomization for a 2x2 crossover study may be 
carried out through tables of random numbers or randomization procedures implemented by 
statistical software. 
Replicated crossover design
6
This design is recommended for bioequivalence studies of formulations with modified-release 
dosage or highly variable products (intra-individual variation coefficient ≥30%), including the 
quick-release, and modified-release ones and other oral administration products. 
The same test and reference formulation batches shall be used for this design for replicated 
administration. The periods shall be sufficiently spaced (washout) to assure non-existence of 
carryover effects. 
Four-sequence and two-period design (Balaam’s design) 
In this design, test (T) and reference (R) will be taken in two period and four sequence 
pattern in order to compare two formulations of a drug.  
15
Two-sequence and four-period design 
In this design, there will be four periods and two sequences. To know the typical drug 
concentration variations in human subjects regarding test and references, number of periods can 
be increased.  
Four-sequence and four-period design 
Here the design consists of four periods and four sequences. It is a most typical replicated 
crossover design. 
Two-sequence and three-period design 
In this design, subjects will undergo three period and two sequence design.  
Crossover design for three medications (William’s design) 
(William‘s design with T1 = test 1, T2 = test 2, R = reference) 
16
In order to compare three formulations of a drug, there are a total of three possible comparison 
pairs among formulations: formulation 1 versus formulation 2, formulation 1 versus formulation 
3, and formulation 2 versus formulation 3.  
1.3.1 Types of BA/BE Studies
7
Fasting Study 
After an overnight fast of at least 10 hrs, subjects are made to continue to fast for up to 4 hours 
after dosing. 
Fed Study 
After an overnight fast of at least 10 hrs, subjects are given a high calorie-high fat 
breakfast 60 minute prior to administration of the drug product. 
1.3.2 Quality Control and Quality Assurance
8
Quality Control: 
The principal investigator by careful planning, assigning responsibilities to well qualified study 
personnel, through continuous review, verifies and maintains desired level of quality in the 
study. 
Quality Assurance: 
Review will be carried out by the QA department to confirm that deviations if any from 
approved protocol or SOP are adequately documented.
17
1.3.3 Ethical Considerations
8
Basic Principles 
The study will be carried out in accordance with the provisions of current versions of ICH 
guidance for Good Clinical Practices and ICMR guidance for biomedical research on human 
subjects. 
Ethics Committees 
The protocol and informed consent will be submitted to the IRB/IEC for review. Upon 
approval, the study will be conducted as per the approved protocol.
Informed Consent Form 
A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject's decision to participate. Informed consent is documented by means of a written, signed 
and dated informed consent form. A reference copy of the form shall be given to the respective 
subjects. 
Termination of Study 
The sponsor reserves the right to discontinue the study at any time, upon IRB approval. Reasons 
for the termination will be provided to the subjects and IRB. The investigator reserves the right 
to discontinue the study at any time for the reasons of subject safety and welfare. The Ethics 
Committee may terminate the study, if there are major violations of ethics or due to any serious 
adverse effects. 
Subject Compensation 
The subjects will be paid an adequate compensation by the Ethics Committee on account of their 
time participation in the trail and for any inconvenience caused. In case of discontinuation from 
study before completion of study, the compensation will be paid according to the compensation 
policy. 
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Insurance Policy 
The study will be covered by an insurance contract, wherein all subjects participating in any 
study is covered for indemnity and medical expenses. 
Drawing and Disposal of Plasma Samples 
The plasma samples should be drawn only when a proper validated bio analytical method is 
available and disposed after submission of study report. 
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2. REVIEW OF LITERATURE
Lamotrigine is a phenyltriazine used in the treatment of epilepsy and bipolar disorder type I. 
Following are the literature review results retrieved for the clinical studies and meta-analysis 
carried out on lamotrigine. 
In 2012, Ruiz et al, stated that the test and reference products of lamotrigine 100 mg tablets 
complied with the regulatory criteria for equivalence with respect to rate and extent of absorption 
according to the guidances of Instituto Nacional de Vigilancia de Medicamentos y Alimentos 
and FDA through a single-dose, two treatment, two-period, two-sequence crossover study in 
healthy Thai male volunteers.9 
In 2012, Perez-Lloret S et al, stated that the test and reference products lamotrigine 50 mg tablets 
met the regulatory criteria for bioequivalence and suggested that bioequivalence studies 
evaluating 50-mg doses of Lamotrigine are feasible and recommended, since such doses may 
minimize the risk of severe rash or Stevens-Johnson Syndrome through the a randomized, single- 
dose, 2-period, 2-sequence crossover study in fasting healthy volunteers.10 
In 2008, Srichaiya A et al, stated that test and reference product of lamotrigine 100-mg tablets 
were bioequivalent in the healthy Thai male subjects, based on the US FDA's regulatory 
definition through a randomized, single-dose, two-period, two-sequence crossover study.11 
In 2007, Makus KG et al, stated that some patients may experience loss of seizure control when 
generic lamotrigine is substituted for the branded formulation through a case-series analysis of 
Health Canada adverse-reaction forms submitted to pharmacists by physicians were retrieved, 
and from a physician chart audit and survey.12 
In 2012, Hartung DM et al, stated that a statistically significant increase in emergency visits, 
hospitalizations or condition-specific encounters was not observed following the switch from 
brand to generic lamotrigine, although a type II error cannot be ruled out through a retrospective 
cohort-crossover design using state Medicaid claims data from July 2006 through June 2009.13 
In 2008, Calabrese JR et al, stated that lamotrigine 200 mg/day demonstrated significant 
antidepressant efficacy on the 17-item HAM-D, HAM-D Item 1, MADRS, CGI-S, and CGI-I 
compared with placebo through a double-blind placebo-controlled study of lamotrigine 
monotherapy in outpatients with bipolar I depression.14 
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In 2006, Brown EB et al, stated that patients with acute bipolar I depression had statistically 
significantly greater improvement in depressive and manic symptoms, more treatment-emergent 
adverse events, greater weight gain, and some elevated metabolic factors with 
olanzapine/fluoxetine than lamotrigine through a 7-week, randomized, double-blind trial.16 
In 2000, Calabrese JR et al, indicated that lamotrigine monotherapy is a useful treatment for 
some patients with rapid-cycling bipolar disorder through a double-blind, placebo-controlled, 
prophylaxis study of lamotrigine in rapid-cycling bipolar disorder.17 
In 2003, Barbosa L et al, stated potential efficacy of the antidepressant profile of lamotrigine and 
possible role of lamotrigine as an augmentation agent in depression through a double-blind, 
randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients 
concomitantly treated with fluoxetine for resistant major depressive episodes.18 
In 2009, van der Loos ML et al, stated that lamotrigine was found effective and safe as add-on 
treatment to lithium in the acute treatment of bipolar depression through a multicenter, double- 
blind, placebo-controlled trial to assess the efficacy and safety of lamotrigine as add-on treatment 
to lithium in bipolar depression.19 
In 2005, Biton V et al, stated that adjunctive lamotrigine is effective in the treatment of primary 
generalized tonic-clonic seizures and has a favorable tolerability profile through a double-blind, 
placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures.20 
In 1993, Matsuo F stated that lamotrigine was safe, effective, and well tolerated as add-on 
therapy for refractory partial seizures through a placebo‐controlled study of the efficacy and 
safety of lamotrigine in patients with partial seizures.21 
In 2007, Naritoku DK et al, stated that once-daily adjunctive lamotrigine extended-release 
compared with placebo effectively reduced partial seizure frequency and was well tolerated in a 
baseline phase, a 7-week double-blind escalation phase, and a 12-week double-blind trial.22 
In 2004, McElroy SL et al, stated that bipolar I patients experienced sustained improvement in 
depressive symptoms without evidence of mood destabilization through A 52-week, open-label 
continuation study of lamotrigine in the treatment of bipolar depression.15 
21
In 1999, Duchowny M et al, stated that lamotrigine was effective for the adjunctive treatment of 
partial seizures in children and demonstrated an acceptable safety profile through a placebo- 
controlled trial of lamotrigine add-on therapy for partial seizures in children.23
22
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3. AIM AND OBJECTIVES
Primary Objective: 
To evaluate the relative bioavailability of Lamotrigine orally disintegrating tablets 50 mg, 
of Edict Pharmaceuticals, Chennai, India and LAMICTAL® ODT™ (Lamotrigine) 
Orally Disintegrating Tablets 50 mg of GlaxoSmithKline, Research Triangle Park, NC 
27709 in healthy, adult, human subjects under fed conditions. 
Secondary Objective: 
The other objectives of this study are to identify, assess, treat, and report any adverse 
events and ensure safety of the subjects during the course of the clinical study.
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3.1 Description of the Investigational Product: 
Lamotrigine chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, its molecular 
formula is C9H7N5Cl2, and its molecular weight is 256.09. Lamotrigine is a white to pale 
cream-colored powder and has a pKa of 5.7. Lamotrigine is very slightly soluble in water 
(0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural 
formula is: 
The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. 
In animal models designed to detect anticonvulsant activity, lamotrigine was effective in 
3.2 Indications and Usage 
Epilepsy 
Adjunctive Therapy: Lamotrigine is indicated as adjunctive therapy for the following seizure 
types in patients ≥2 years of age: Partial seizures, Primary generalized tonic-clonic seizures, and 
Generalized seizures of Lennox-Gastaut syndrome. 
Monotherapy: Lamotrigine is indicated for conversion to monotherapy in adults (≥16 years of 
age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, 
phenobarbital, primidone, or valproate as the single antiepileptic drug.
Bipolar Disorder 
Lamotrigine is indicated for the maintenance treatment of Bipolar I Disorder to delay the time to 
occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 
years of age) treated for acute mood episodes with standard therapy.  
4.DRUG PROFILE
3.3 Clinical Pharmacology 
Mechanism of Action 
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preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) 
tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) 
tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling 
model in rats both during kindling development and in the fully kindled state. The relevance 
of these models to human epilepsy, however, is not known. 
One proposed mechanism of action of lamotrigine, the relevance of which remains to be 
established in humans, involves an effect on sodium channels. In vitro pharmacological 
studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing 
neuronal membranes and consequently modulating presynaptic transmitter release of 
excitatory amino acids (e.g., glutamate and aspartate). 
3.4 Pharmacokinetics: 
Absorption  
Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-
pass metabolism (absolute bioavailability is 98%). The bioavailability is not affected by food. 
Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours following drug 
administration. The lamotrigine chewable/dispersible tablets were found to be equivalent, 
whether they were administered as dispersed in water, chewed and swallowed, or swallowed 
as whole, to the lamotrigine compressed tablets in terms of rate and extent of absorption. In 
terms of rate and extent of absorption, lamotrigine orally disintegrating tablets whether 
disintegrated in the mouth or swallowed whole with water were equivalent to the lamotrigine 
compressed tablets swallowed with water. 
Distribution  
Estimates of the mean apparent volume of distribution of lamotrigine following oral 
administration ranged from 0.9 to 1.3 L/kg. volume of distribution is independent of dose and 
is similar following single and multiple doses in both patients with epilepsy and in healthy 
volunteers. 
Metabolism 
Lamotrigine is metabolized predominantly by glucuronic acid conjugation; the major 
metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of 240 mg of 
14C-lamotrigine (15 μCi) to 6 healthy volunteers, 94% was recovered in the urine and 2% was 
recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine 
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(10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite 
(0.14%), and other unidentified minor metabolites (4%). 
Elimination 
The elimination half-life and apparent clearance of Lamotrigine following administration of 
Lamotrigine to adult healthy volunteers is summarized below. 
Adult Study Population 
Tmax: Time of 
Maximum Plasma 
Concentration 
(hr) 
t½: 
Elimination Half-
life 
(hr) 
Cl/F: 
Apparent Plasma 
Clearance 
(mL/min/kg) 
Healthy volunteers taking no other 
medications: 
Single-dose lamotrigine 2.2 (0.25-12.0) 
32.8 
(14.0-103.0) 
0.44 
(0.12-1.10) 
Multiple-dose lamotrigine 1.7 (0.5-4.0) 
25.4 
(11.6-61.6) 
0.58 
(0.24-1.15) 
3.5 Dosage Forms and Strengths 
Tablets, Chewable Dispersible Tablets, and Chewable Dispersible Tablets: 25 mg, 100 mg, 150 
mg, and 200 mg
3.6 Adverse Drug Reactions 
Lamotrigine has been administered to 6,694 individuals for whom complete adverse reaction 
data was captured during all clinical trials, only some of which were placebo controlled. During 
these trials, all adverse reactions were recorded by the clinical investigators using terminology 
of their own choosing. To provide a meaningful estimate of the proportion of individuals having 
adverse reactions, similar types of adverse reactions were grouped into a smaller number of 
standardized categories using modified COSTART dictionary terminology. The frequencies 
presented represent the proportion of the 6,694 individuals exposed to lamotrigine who 
experienced an event of the type cited on at least one occasion while receiving lamotrigine. All 
reported adverse reactions are included except those already listed in the previous tables or 
elsewhere in the labeling, those too general to be informative, and those not reasonably 
associated with the use of the drug.
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Adverse reactions are further classified within body system categories and enumerated in order 
of decreasing frequency using the following definitions: frequent adverse reactions are defined 
as those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 
1/100 to 1/1,000 patients; rare adverse reactions are those occurring in fewer than 1/1,000 
patients. 
Body as a Whole: Infrequent: Allergic reaction, chills, and malaise. 
Cardiovascular System: Infrequent: Flushing, hot flashes, hypertension, palpitations, postural 
hypotension, syncope, tachycardia, and vasodilation.  
Dermatological: Infrequent: Acne, alopecia, hirsutism, maculopapular rash, skin discoloration, 
and urticaria. Rare: Angioedema, erythema, exfoliative dermatitis, fungal dermatitis, herpes 
zoster, leukoderma, multiforme erythema, petechial rash, pustular rash, Stevens-Johnson 
syndrome, and vesiculobullous rash. 
Digestive System: Infrequent: Dysphagia, eructation, gastritis, gingivitis, increased appetite, 
increased salivation, liver function tests abnormal, and mouth ulceration. Rare: Gastrointestinal 
hemorrhage, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic colitis, 
hepatitis, melena, stomach ulcer, stomatitis, and tongue edema. 
Endocrine System: Rare: Goiter and hypothyroidism. 
Hematologic and Lymphatic System: Infrequent: Ecchymosis and leukopenia. Rare: Anemia, 
eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis, 
lymphocytosis, macrocytic anemia, petechia, and thrombocytopenia. 
Metabolic and Nutritional Disorders: Infrequent: Aspartate transaminase increased. Rare: 
Alcohol intolerance, alkaline phosphatase increase, alanine transaminase increase, 
bilirubinemia, general edema, gamma glutamyl transpeptidase increase, and hyperglycemia. 
Musculoskeletal System: Infrequent: Arthritis, leg cramps, myasthenia, and twitching. Rare: 
Bursitis, muscle atrophy, pathological fracture, and tendinous contracture. 
Nervous System: Frequent: Confusion and paresthesia. Infrequent: Akathisia, apathy, aphasia, 
central nervous system (CNS) depression, depersonalization, dysarthria, dyskinesia, euphoria, 
hallucinations, hostility, hyperkinesia, hypertonia, libido decreased, memory decrease, mind 
racing, movement disorder, myoclonus, panic attack, paranoid reaction, personality disorder, 
psychosis, sleep disorder, stupor, and suicidal ideation. Rare: delirium, delusions, dysphoria, 
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dystonia, extrapyramidal syndrome, faintness, grand mal convulsions, hemiplegia, hyperalgesia, 
hyperesthesia, hypokinesia, hypotonia, manic depression reaction, muscle spasm, neuralgia, 
neurosis, paralysis, and peripheral neuritis. 
Respiratory System: Infrequent: Yawn. Rare: Hiccup and hyperventilation. 
Special Senses: Frequent:  Amblyopia. Infrequent: Abnormality of accommodation, 
conjunctivitis, dry eyes, ear pain, photophobia, taste perversion, and tinnitus. Rare: Deafness, 
lacrimation disorder, oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, and visual field 
defect. 
Urogenital System: Infrequent: Abnormal ejaculation, hematuria, impotence, menorrhagia, 
polyuria, and urinary incontinence. Rare: Acute kidney failure, anorgasmia, breast abscess, 
breast neoplasm, creatinine increase, cystitis, dysuria, epididymitis, female lactation, kidney 
failure, kidney pain, nocturia, urinary retention, and urinary urgency. 
3.7 Overdosage 
Human Overdose Experience 
Overdoses involving quantities up to 15 g have been reported for lamotrigine, some of which 
have been fatal. Overdose has resulted in ataxia, nystagmus, increased seizures, decreased level 
of consciousness, coma, and intraventricular conduction delay. 
Management of Overdose 
There are no specific antidotes for lamotrigine. Following a suspected overdose, hospitalization 
of the patient is advised. General supportive care is indicated, including frequent monitoring of 
vital signs and close observation of the patient. If indicated, emesis should be induced; usual 
precautions should be taken to protect the airway. It should be kept in mind that lamotrigine is 
rapidly absorbed. It is uncertain whether hemodialysis is an effective means of removing 
lamotrigine from the blood. In 6 renal failure patients, about 20% of the amount of lamotrigine in 
the body was removed by hemodialysis during a 4-hour session. A poison control center should 
be contacted for information on the management of overdosage of lamotrigine. 
3.8 Use in Specific Populations 
Pregnancy 
Teratogenicity Effects: No evidence of teratogenicity was found in mice, rats, or rabbits when 
lamotrigine was orally administered to pregnant animals during the period of organogenesis at 
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doses up to 1.2, 0.5, and 1.1 times, respectively, the highest usual human maintenance dose (i.e., 
500 mg/day). However, maternal toxicity and secondary fetal toxicity producing reduced fetal 
weight and/or delayed ossification were seen in mice and rats, but not in rabbits at these doses. 
Teratology studies were also conducted using bolus intravenous administration of the isethionate 
salt of lamotrigine in rats and rabbits. In rat dams administered an intravenous dose at 0.6 times 
the highest usual human maintenance dose, the incidence of intrauterine death without signs of 
teratogenicity was increased. 
Labor and Delivery 
The effect of LAMICTAL on labor and delivery in humans is unknown. 
31
32
5.1 Investigational Plan 
Overall Study Design and Plan 
The study was an open-label, balanced, randomized, two-treatment, two-period, 
twosequence, single-dose, two-way crossover, bioequivalence study in healthy, adult, human 
subjects under fed conditions comparing equal doses of the test and reference products. Blood 
sampling was carried at pre-defined intervals up to 144.00 hours after dosing in each period. 
Subjects were confined at the clinical facility from at least 11.00 hours prior to dosing to at 
least 24.00 hours post dose. The interval between the two treatment period was 14 days.
Study Population: 32, healthy, adult, human subjects
Study type: FFed conditions
Discussion of Study Design and the Choice of Control Group 
Edict Pharmaceuticals, Chennai, India seeks approval of a generic version of Lamotrigine 
tablets 50 mg for which demonstration of bioequivalence to the reference listed product. 
LAMICTAL® ODT™ (Lamotrigine) Orally Disintegrating Tablets 50 mg of 
GlaxoSmithKline, Research Triangle Park, NC 27709 was required. After literature review 
and considering bioequivalence standards, intra-subject variability and possibility of drop 
outs, the protocol for study was written incorporating sufficient number of subjects to be 
enrolled in the study. The protocol was reviewed and approved by the IEC prior to 
commencement of the study. The study was designed based on the known pharmacokinetics 
profile of Lamotrigine tablets and general accepted standards for the conduct of 
bioequivalence studies. 
Data from subjects who completed both the periods of the study was used in the 
pharmacokinetic and statistical evaluation according to the protocol. In order to minimize any 
possibility of a carryover effect as per protocol, 14 days washout period was maintained in this 
study. Bioequivalence was determined by statistical comparison of  log-transformed data of 
Cmax, AUC0-t and AUC0-∞ for the test and reference products for Lamotrigine. 
5.METHODOLOGY
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5.3 Selection of Study Population 
All subjects underwent a screening procedure (performed within 29 days) prior to the start of 
the study. Medical history and detailed demographic data were recorded. Each subject 
underwent a complete general physical examination (including but may not be limited to an 
evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), 
vital sign assessments, 12-lead electrocardiogram (ECG), X-ray and clinical laboratory 
assessments. Further, the subjects were selected on the basis of following inclusion and 
exclusion criteria. 
Inclusion Criteria 
Volunteers meeting all of the following criteria were considered for enrollment in the 
study: 
 Healthy human volunteers of age 18-45 years with a Body Mass Index (BMI)
ranges between 18.50 kg/m2 and  24.99 kg/m2 (according to the formula of BMI
= weight (kg) / [height (m)]2).
 Subjects who have no evidence of underlying disease during screening and
check-in and whose screening is performed within 29 days of check-in.
5.2 Independent Ethics Committee (IEC)  
The study protocol with informed consent documents (English and Vernacular 
languages) was reviewed and approved by Independent Ethics Committee (The Chennai 
Ethics Committee).
Ethical Conduct of the Study 
The study was conducted as per the ICMR Ethical Guidelines for Biomedical Research   on 
Human Subjects (2006), “Good Clinical Practices for clinical research India” guidelines -
Schedule Y (Amended version 2005), ICH-GCP guidelines and accordance with the 
Declaration of Helsinki (Seoul, October 2008). No subject was enrolled into the study without 
obtaining written informed consent and subjects were under medical supervision throughout 
their stay in the clinical facility to ensure safety and well being of the subjects. 
Subject Information and Consent 
Written informed consent was obtained from each subject prior to screening and also prior to 
enrollment in to the study. Subjects were asked to read the informed consent documents 
which were followed by a presentation by the trained study personnel. 
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 Subjects whose screening laboratory values are within normal limits or
considered by the Physician or Principal/Clinical Investigator to be of no clinical
significance.
 Non- or ex-smokers. Ex-smokers are defined as someone who has completely
stopped smoking for at least the past 03 months.
 Willing to take ovo-lacto vegetarian diet.
 Generally healthy as documented by the medical history, physical examination
(including but may not be limited to an evaluation of the cardiovascular,
gastrointestinal, respiratory and central nervous systems) and vital sign
assessments.
 Generally healthy as documented by 12-lead electrocardiogram (ECG), X-Ray,
and clinical laboratory assessments.
 Generally healthy as documented by gynecological examination and breast
examination (for female subjects in period I only).
 Generally healthy as documented by Pregnancy test (for female subjects only).
 Any abnormalities/deviations from the acceptable range that might be considered
clinically relevant by the study physician or investigator will be evaluated as
individual cases.
 Female subjects within normal limits or clinically non-significant laboratory
evaluation results for FSH & LH (for female subjects only).
 Female subjects of childbearing potential;
 Practicing an acceptable non-hormonal contraceptive method of birth  control
after consulting with principal investigator; and/or
 Surgically sterile (bilateral tubal ligation).
Exclusion Criteria 
History or presence of significant:  

Evidence of allergy or known hypersensitivity to Lamotrigine or other related
drugs.
 Patients with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver
disease and recently overcome or active existing tinnitus.
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 Any major illness in the last three months or any significant ongoing chronic
medical illness.
 Renal or liver impairment.
 History of current gastro-intestinal diseases influencing drug absorption.
 History of drug abuse within 03 months (including benzodiazepines, opioids,
cocaine, Barbiturates, THC and amphetamine etc.)
 History of alcohol addiction or abuse within the past one year.
 High caffeine (more than 05 cups of coffee or tea/day) or tobacco (more than 05
packets of gutka/day) consumption.
 Consumption of grapefruit and/ or its juice, and poppy containing foods within
72.00 hours prior to clinic admission and throughout the entire study.
 Subject who had participated in any other study within the 03 months of check-
in.
 History of difficulty in swallowing.
 Any blood donation / excess blood loss within 03 months of check-in.
 History of difficulty in accessibility of veins.
 Ingestion of any hormonal agent at any time in 14 days prior to start of study.
 Pregnant females.
 Breast feeding females.
 Use of hormone replacement therapy within 06 months prior to dosing.
 Female subjects with child bearing potential using prohibited contraceptive
method (oral, injectable or implantable hormonal agents).
Withdrawal Criteria 
The investigator may withdraw a subject from the study for reasons which include but not 
limited to: 
 Adverse event which warrants withdrawal of subject.
 Willful withholding of information by subjects.
 Failure of drug administration.
 Failure of cannulation.
36
 Undue difficulty in obtaining blood sample.
 Non-compliance with procedures.
 Premature termination of study.
 It is in the best interest of the study participant that he be withdrawn.
 Withdrawal of consent for participation in the study by the subject.
 Occurrence of emesis at or before two times of median tmax.
 The subject withdrawal during the study was handled as per in-house standard
operating procedure with adequate documentation.
5.4 Treatments 
 The subjects were administered a single oral dose of test product Lamotrigine or the 
reference product LAMICTAL® ODT™ in sitting posture with about 20 mL of water to 
wet the mouth before drug administration . After swallowing of 20 mL of water oro-
dispersible tablets of test or reference product was placed on the tongue of the subjects at 
the scheduled time of dosing and allowed to disintegrate on the tongue for 30 seconds. 
At the end of 30 seconds subject’s tongue was checked for complete disintegration of 
the tablet. After disintegration of the tablet 220 mL of water was given at ambient 
temperature on period I and Period II under fed conditions. Compliance for dosing 
after drug administration was assessed by examination of the oral cavity by qualified 
study personnel. The order of receiving the test and reference product for each subject 
during the study was determined according to SAS® software (version 9.2) generated 
randomization schedule. The randomization was balanced and the code was kept 
under controlled access. 
Treatments Administered 
The subjects were given a single oral dose of either the test product [Lamotrigine 
tablets 50 mg] or reference product [LAMICTAL® ODT™ tablets, 50 mg] in each 
period as per the randomization schedule separated by a washout period of 14 days. 
Subjects S16 and Subject S30 did not report to the facility. 
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Method of Assigning Subjects to Treatment Groups 
The eligible subjects, who fulfilled the inclusion and exclusion criteria for the study, 
were  enrolled and  randomly assigned to one of the possible sequences of test product 
(T) and reference product (R) (either TR or RT) in consecutive order using 
SAS® (SAS Institute Inc., USA) version 9.2. 
The randomization was balanced and the code was kept under controlled 
access. The study personnel involved in the sample analysis were kept blinded 
from the randomization code during entire study. 
Selection of Doses in the Study 
As per the reference listed drug, regulatory recommendations, Lamotrigine tablets 50 
mg was considered as relatively safe dose to administer in healthy, adult, human 
subjects and chosen to achieve sufficient plasma levels to characterize the 
pharmacokinetic profile. 
Selection and Timing of Dose for Each Subject 
The subjects were given a single oral dose of the test product Lamotrigine or reference 
product LAMICTAL® ODT™ 20 mL of water to wet the mouth before drug 
administration . After swallowing of 20 mL of water oro-dispersible tablets of test or 
reference product will be placed on the tongue of the subjects at the scheduled time of 
dosing and allowed to disintegrate on the tongue for 30 seconds.  At the end of 30 
seconds subject’s tongue will be checked for complete disintegration of the tablet. 
After disintegration of the tablet 220 mL of water  between (10.00 Hrs) to (10.22 Hrs) 
at staggered intervals as per the randomization schedule in each period with a 
washout period of 14 days. Individual demographic data of subjects can be 
found in table 1. The date and time of dosing of each subject for the two periods 
are given in the table 2. 
Blinding 
The study was an open label randomized study. Since bioequivalence studies involve a 
comparison of pharmacokinetic profiles, which are not subjective measurements, 
blinding was not deemed necessary for this study. However, bioanalytical analysts 
were blinded to the randomization during the course of the analysis and until the 
results were processed by the statistical department and reported. 
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Table 1 Individual Demographic Data of All Subjects (N=32) Participated in the Study 
Subject 
No 
Age 
(yrs) 
Height 
(cm) 
Weight  
(kg) 
BMI 
(Kg/m2) 
Gender Race Smoking status 
S01 25 170 57 19.72 Male Asian Non-smoker 
S02 32 157 58 23.53 Male Asian Non-smoker 
S03 40 167 68 24.38 Male Asian Non-smoker 
S04 26 169 53 18.55 Male Asian Non-smoker 
S05 33 165 68 24.97 Male Asian Non-smoker 
S06 30 161 52 20.06 Male Asian Non-smoker 
S07 37 173 74 24.72 Male Asian Non-smoker 
S08 29 170 70 24.22 Male Asian Non-smoker 
S09 23 179 72 22.47 Male Asian Non-smoker 
S10 31 166 68 24.67 Male Asian Non-smoker 
S11 21 174 61 20.14 Male Asian Non-smoker 
S12 21 174 57 18.82 Male Asian Non-smoker 
S13 20 160 51 19.92 Male Asian Non-smoker 
S14 27 172 74 24.72 Male Asian Non-smoker 
S15 32 169 70 24.5 Male Asian Non-smoker 
S16 18 170 59 20.41 Male Asian Non-smoker 
S17 19 172 56 18.92 Male Asian Non-smoker 
S18 39 165 60 22.03 Male Asian Non-smoker 
S19 26 173 85 28.4 Male Asian Non-smoker 
S20 25 178 68 21.46 Male Asian Non-smoker 
S21 41 176 76 24.53 Male Asian Non-smoker 
S22 27 172 72 24.33 Male Asian Non-smoker 
S23 24 168 63 22.32 Male Asian Non-smoker 
S24 32 166 58 21.04 Male Asian Non-smoker 
S25 25 178 63 19.88 Male Asian Non-smoker 
S26 31 177 62 19.79 Male Asian Non-smoker 
S27 38 178 76 23.98 Male Asian Non-smoker 
S28 42 158 58 23.23 Male Asian Non-smoker 
S29 19 174 57 18.82 Male Asian Non-smoker 
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Table 2: Date, Time of Dosing, Randomization order and Dosing Status of Subjects 
Treatment Compliance 
The trained clinical study personnel ensured that dosing was appropriately carried out 
by closely monitoring the subjects. Compliance for dosing after drug administration 
was assessed by examination of the oral cavity. The dosing was done by adequately 
trained personnel under the supervision of principal investigator/clinical investigator 
and quality assurance auditor. Dosing was done and the details were recorded in 
individual raw data forms.
Pharmacokinetic and Safety Variables 
Pharmacokinetic and Safety Measurements  
The study was designed to evaluate the relative bioavailability of test and reference 
products of Lamotrigine tablets 50 mg. Therefore efficacy was not measured, instead 
pharmacokinetic profile (in terms of rate and extent of absorption) of both test and 
reference products were evaluated based on measured concentration of drug in the 
human plasma sample collected in clinical phase. 
Safety assessments were done based on clinical observations, laboratory data at the 
beginning and at the end of the study and evaluation of the AE’s observed during the 
course of the study.
The date, time, randomization order and dosing status of subjects are described in 
table 2 . Schedule of assessment was described in table 3.
Subject Randomization Order Scheduled 
 Time of Dosing Dosing Status 
No. Period I Period II Period I(20 Dec 13)
Period II
(03 Jan 2014) Period I Period II
S01 R T 10:01 10:00 Dosed Dosed
S02 T R 10:03 10:02 Dosed Dosed
S03 R T 10:05 10:04 Dosed Dosed
S04 T R 10:06 10:06 Dosed Dosed
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Subject Randomization Order Scheduled Time of Dosing Dosing Status 
No. Period I Period II Period I Period II  ) Period I Period II
S05 T R 10:08 10:08 Dosed Dosed
S06 R T 10:10 10:10 Dosed Dosed
S07 R T 10:12 10:12 Dosed Dosed
S08 T R 10:14 10:14 Dosed Dosed
S09 T R 10:17 10:16 Dosed Dosed
S10 R T 10:18 10:19 Dosed Dosed
S11 R T 10:20 10:20 Dosed Dosed
S12 T R 10:22 10:22 Dosed Dosed
S13 R T 10:01 10:00 Dosed Dosed
S14 T R 10:03 10:02 Dosed Dosed
S15 R T 10:05 10:04 Dosed Dosed
S16 T Not reported 10:06 Not reported Dosed Not dosed 
S17 T R 10:08 10:08 Dosed Dosed
S18 R T 10:10 10:10 Dosed Dosed
S19 R T 10:12 10:12 Dosed Dosed
S20 T R 10:14 10:14 Dosed Dosed
S21 R    T 10:16 10:16 Dosed Dosed
S22 T R 10:18 10:18 Dosed Dosed
S23 R T 10:00 10:00 Dosed Dosed
S24 T R 10:02 10:03 Dosed Dosed
S25 R T 10:04 10:05 Dosed Dosed
S26 T R 10:06 10:15 Dosed Dosed
S27 T R 10:08 10:09 Dosed Dosed
S28 R T 10:10 10:11 Dosed Dosed
S29 T R 10:12 10:13 Dosed Dosed
S30 R Not reported 10:14 Not reported Dosed Not dosed 
S31 R T 10:16 10:16 Dosed Dosed
S32 T R 10:18 10:18 Dosed Dosed
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(20 Dec 13) (03 Jan 14)
Table 3: Schedule of assessment 
Period I Period II Events 
Assessment 
Informed 
Consent 
followed by 
Screening 
Informed 
Consent 
followed by 
Check-in 
Dosing Check-out 
Ambulatory Washout 
period 
Check-
in Dosing 
Check
-out 
Ambulatory Post-study 
assessment 
Study days -28 to 00 day 00 01 02 02,03,04, 05, 06, 07 00 to 14 14 15 16 
16, 17, 18, 
19, 20, 21 21 
Medical history   N/AP N/AP N/AP N/AP  N/AP N/AP N/AP N/AP 
Physical 
examination 
  N/AP  N/AP N/AP  N/AP  N/AP N/AP 
Vitals      N/AP     N/AP 
Lab tests  N/AP N/AP N/AP N/AP N/AP N/AP N/AP N/AP N/AP  
X ray and ECG  N/AP N/AP N/AP N/AP N/AP N/AP N/AP N/AP N/AP N/AP 
Urine screen 
for drugs of 
abuse 
N/AP  N/AP N/AP N/AP N/AP  N/AP N/AP N/AP N/AP 
Alcohol breath 
test 
N/AP  N/AP N/AP  N/AP  N/AP N/AP  N/AP 
Well being 
questionnaire 
N/AP N/AP    N/AP N/AP    N/AP 
Monitoring for 
AE 
N/AP           
42
Appropriateness of Measurements 
The selection and timing of blood samples for pharmacokinetic analysis were judged 
appropriately for characterizing the pharmacokinetic profiles for given treatment and 
dose administered. The pharmacokinetic parameters used / derived in this study are 
widely used and accepted in the assessment of the pharmacokinetic equivalence of 
two treatments. The safety assessments conducted in this study were judged 
appropriately by the investigators and are documented in the raw data sheets / CRF’s 
which served as source documents. 
Primary Pharmacokinetic Variable(s) 
Cmax, AUC0-t and AUC0-∞ are the primary pharmacokinetic variables, as the 90 
confidence intervals are applied for these parameters and tmax, t1/2, Kel, Kel_Lower, 
Kel_Upper and AUC_%Extrap_obs was considered as secondary variables. 
Drug Concentration Measurements 
According to the guidelines, the determination of bioavailability is dependent on the 
reliable, precise and accurate measurement of the concentration levels of the active 
ingredient of the drug product in blood, plasma, serum or other biological matrices. 
Totally 23 samples were collected per subject in each period. At pre-dose (00.00 hr), 
00.25, 00.50, 00.75, 01.00, 01.50, 02.00, 02.50, 03.00, 04.00, 05.00, 06.00, 08.00, 
10.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 and 144.00 hours after 
dosing. The volume of blood collected after dosing at each time point was 06 mL and 
post study assessments 08 mL of blood was collected. The total volume of blood 
collected from each subject throughout the study did not exceed 316 mL. Blood 
samples were drawn using sterile, disposable syringes from indwelling intravenous 
cannula placed in the cubital fossa and transferred into pre-labelled K2EDTA 
Vacutainers. Vacutainers were placed upright in a rack kept in wet ice bath until 
centrifugation. Heparin-lock technique was used to prevent clotting of the blood in 
the indwelling catheter. Before each in-house blood draw, around 0.5 mL of blood 
was discarded to prevent the heparin in the catheter interfering during analysis. The 
details of sample collection were provided in table 4.  
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 Table 4: Details of Sample Collection 
After collection of blood samples from all the subjects at each time point, the blood 
samples were centrifuged at 4000 RPM for 10 minutes at 4°C to separate the plasma 
and the plasma samples were transferred into pre-labeled polypropylene tubes into 
double aliquots. These samples were stored at temperature at (-)25°C at the clinical 
site. At the end of the study, samples were transferred to the bioanalytical facility and 
stored at a temperature below (-) 70oC in ultra low temperature freezer until analysis.  
The pharmacokinetic parameters (Primary parameters: Cmax, AUC0-t and AUC0-∞ and 
Secondary parameters: tmax, t1/2, Kel, Kel_Lower, Kel_Upper and AUC_%Extrap_obs) were 
estimated in order to characterize rate and extent of absorption of the investigational 
drug products. 
Data Quality Assurance 
The quality assurance unit played an integral role throughout the study. The conduct 
of the study and the data generated during the study, together with this report which 
reflect the raw data were inspected and audited by the quality assurance unit for 
conformance to study protocol, in house SOPs, GCP and GLP.
Total No. of subjects as per protocol 32 
Total No. of subjects enrolled 32 
Total No. of periods 02 
Total No. of sampling points  23 / subject / period 
Total No. of samples to be collected 
(As Per Protocol) 1472 
Total No. of samples to be collected 
(As Per Subjects Enrolled) 1472 
(Period I) 715 
Total No. of  samples collected 
(Period II) 687 
1402 
Total number of missing samples  70 
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5.5 Statistical Methods Planned in the Protocol and Determination of Sample Size 
Statistical and Analytical Plans 
Statistical analysis was carried out using the SAS® statistical software, version: 9.2 of 
SAS Institute Inc, USA. The pharmacokinetic and statistical analyses were performed 
on subjects who completed both the periods of the study and who have been analyzed 
in the bioanalytical department. The descriptive statistics (mean, median, minimum, 
maximum, standard deviation, coefficient of variation, and geometric mean) for the 
pharmacokinetic parameters (primary parameters: Cmax, AUC0-t and AUC0-∞ and 
secondary parameters: tmax, t1/2, Kel, Kel_Lower, Kel_upper and AUC_%Extrap_obs) were 
estimated for both test and reference products. The Ln-transformed pharmacokinetic 
parameters (Cmax, AUC0-t and AUC0-∞) were analyzed using an ANOVA model. The 
analysis of variance model included sequence, subjects nested within sequence, 
period and treatment as factors. In order to test the two one-sided test for 
bioequivalence, 90% confidence intervals for the difference between the least square 
mean of treatment was calculated for Ln-transformed Cmax, AUC0-t and AUC0-∞. The 
confidence interval is expressed as percentage difference relative to the LSM of the 
reference treatments.  
Determination of sample size 
The sample size was based on:  
 Expected range of test to reference ratio.
 Coefficient of variation (CV) of the drug.
 Sufficient statistical power to detect 20% difference with the power of
0.8 in Cmax and AUC between test and reference products.
 Regulatory requirements.
Based on the above criteria, a sample size of 32 was chosen for this study. 
Changes in the Conduct of the Study  
Nil  
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STUDY SUBJECTS 
Disposition of Subjects 
A total of 32 healthy, adult human subjects were enrolled into the study.  
Design:  An open-label, balanced, randomized, two-treatment, two-period, two-sequence, 
single-dose, two-way crossover, bioequivalence study of Lamotrigine orally 
disintegrating tablets 50 mg, of Edict Pharmaceuticals, Chennai, India and LAMICTAL® 
ODTTM (Lamotrigine) Orally Disintegrating Tablets 50 mg of GlaxoSmithKline, 
Research Triangle Park, NC 27709  in healthy, adult, human subjects under fed 
conditions. 
Consented to participate 
(N =32) 
 
 
Test (T)  
(N =16) Period I 
Test (T) 
 (N = 15) Period II 
Reference (R) 
(N =15) Period II 
No of subjects completing the study (N =30) 
Subject No S16 
did not report to 
the facility for 
Period II 
Subject No S30 
did not report to 
the facility for 
Period II 
Reference (R) 
(N =16) Period I 
No of subjects included for pharmacokinetic & 
Statistical analysis (N =30) 
Test Product (T): Lamotrigine tablets 50 mg manufactured by Edict Pharmaceuticals, Pvt.Ltd Reference 
Product (R): LAMICTAL® ODTTM (Lamotrigine) Orally Disintegrating Tablets 50 mg of   GlaxoSmithKline, 
Research Triangle Park, NC 27709. 
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6.1 PHARMACOKINETIC EVALUATION
Data Sets Analyzed 
All the 32 enrolled into the study. Of the 32 enrolled subjects, 30 subjects have 
completed. Samples from 30 subjects who completed the study were analyzed to 
determine the concentrations of Lamotrigine. Pharmacokinetic and Statistical analysis were 
performed on data obtained from 30 subjects who completed the study. All 
concentration values below the lower limit of quantification (LLOQ) were set to 
“zero” for all pharmacokinetic and statistical calculations. 
Demographic and Other Baseline Characteristics 
A total of  32 subjects were enrolled into the study and their mean age, height, weight and 
BMI were  28.21years, 169.56 cm, 64.09 kg and 22.04 kg/m2   respectively (Table 
5). All subjects included in the study were Asian.  
Table 5: Summarized Demographic Profile of Subjects 
Demographic details of subjects who participated in the study (N=32) 
Parameter Mean SD Min Max CV% 
Age (years) 28.21 7.09 18 42 25.15
Height (cm) 169.56 6.01 157 179 8.65
Weight (Kg) 64.09 8.49 50 85 13.2
BMI (Kg/m2) 22.04 2.26 18.55 24.97 10.27
Demographic details of subjects who were included in Pharmacokinetic and Statistical analysis (N=30) 
Parameter Mean SD Min Max CV% 
Age (years) 28.86 6.84 19 42 23.71
Height (cm) 169.80 6.05 157 179 3.56
Weight (Kg) 64.73 8.30 51 85 12.82
BMI (Kg/m2) 22.43 2.51 19 28 11.19
Measurements of Treatment Compliance 
The test and reference investigational drug products were administered as per the 
randomization schedule at scheduled time of dosing and there were no deviations in 
6.RESULTS
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drug dosing. The drug administration was done by the trained clinical study personnel 
under the supervision of principal investigator/clinical investigator qualified medical 
personnel and quality assurance auditor.  
Pharmacokinetic Results and Tabulations of Individual Subject Data  
The pharmacokinetic evaluation was carried out at Azidus Laboratories Private Limited, 
Chennai, India. 
Time deviations during sampling were treated as follows: 
The actual time of sample collected were used to calculate pharmacokinetic 
parameters, except for pre-dose samples, which were always reported as zero (00.00 
hour), regardless of time deviations. 
Pharmacokinetic and Statistical Analysis 
The plasma concentrations (ng/mL) for test product (T) and reference product (R) are 
presented in table 6 and table 7. Pharmacokinetic parameters were calculated using 
WinNonlin® software (version 5.3). 
The mean, standard deviation (SD), geometric mean, coefficient of variation (CV %), 
minimum, median, maximum for both test and reference products were calculated for 
Cmax, AUC0-t AUC0-∞, t max, t 1/2, K el, K el_Lower, K  el_Upper and AUC_%Extrap_obs. The 
calculation of these pharmacokinetic parameters is explained in table 8 and table 9. 
Summary of  PK Parameters of test and reference can be found in table 10.
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 Table 6: Individual Subject plasma Lamotrigine Concentrations for Reference Product (R) 
  Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
00.00 00.25 00.50 00.75 01.00 01.50 02.00 02.50 03.00 04.00 05.00 
S01 P1 RT 0.0000 20.8249 111.6906 144.5240 185.2919 309.0141 375.7528 432.4957 515.0929 633.1102 610.7777 
S02 P2 TR 0.0000 221.8911 255.9688 238.5916 275.5863 328.8530 395.3387 466.8757 558.3900 696.6379 728.2911 
S03 P1 RT 0.0000 83.7472 107.1424 221.9649 421.9901 514.7738 594.7749 561.7125 548.7522 666.2595 600.6523 
S04 P2 TR 0.0000 27.6265 115.6455 320.6157 465.6219 573.8004 804.9903 749.1385 865.7792 911.9164 686.0022 
S05 P2 TR 0.0000 28.6770 65.1236 125.1161 235.2104 371.1068 367.0029 452.0485 468.9258 631.3911 564.0789 
S06 P1 RT 0.0000 10.1709 66.8644 124.8643 158.8172 198.6625 277.4177 322.9101 386.7367 706.1143 799.5141 
S07 P1 RT 0.0000 0.0000 69.1267 51.1692 83.9203 149.7109 246.0433 526.1606 502.5535 615.1124 617.1693 
S08 P2 TR 0.0000 39.3839 119.1892 373.2450 419.3301 761.6984 895.4255 851.9083 990.4384 1068.7052 667.0030 
S09 P2 TR 0.0000 21.1197 38.8141 166.9620 219.1438 433.5702 460.8607 573.6954 616.0181 741.9582 636.8978 
S10 P1 RT 0.0000 26.7599 40.1706 92.0755 186.7741 228.0924 274.1369 291.7455 530.0032 683.1614 733.5562 
S11 P1 RT 0.0000 60.8622 83.1457 169.8287 276.5016 493.9605 597.2409 625.2187 686.3983 721.0649 788.4956 
S12 P2 TR 0.0000 111.0542 176.2670 231.9360 344.2079 410.0198 512.6462 638.4188 706.2136 643.6043 639.0473 
S13 P1 RT 0.0000 13.7920 138.4423 125.2380 200.0351 556.3082 641.6744 723.5541 733.2981 839.2519 780.2720 
S14 P2 TR 0.0000 82.0358 177.2475 263.9265 344.2463 309.8328 416.9759 498.5610 590.1040 725.2247 696.6080 
S15 P1 RT 0.0000 12.6684 74.1833 214.5517 264.5958 349.5333 444.4666 538.3086 622.5123 788.2763 934.6100 
S17 P2 TR 0.0000 26.1692 45.6544 81.8669 76.0894 88.0182 108.7450 118.1583 134.6661 276.6367 372.2172 
S18 P1 RT 0.0000 0.0000 42.5295 66.3691 87.2241 189.0775 339.6244 482.3589 538.5866 831.5445 953.8982 
S19 P1 RT 0.0000 99.8521 242.8791 274.4557 379.5948 431.6987 513.3112 639.6197 843.9835 980.9137 965.8487 
S20 P2 TR 0.0000 130.2131 189.5634 398.6276 582.3830 535.3375 753.6918 864.6708 997.7684 1050.2917 960.1431 
S21 P1 RT 0.0000 0.0000 91.0853 40.8165 91.6255 186.6496 322.2382 497.7203 469.6161 752.9886 883.1366 
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Table 6: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Reference Product (R) ………… (Contd) 
   Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
00.00 00.25 00.50 00.75 01.00 01.50 02.00 02.50 03.00 04.00 05.00 
S22 P2 TR 0.0000 204.2835 196.0470 309.5732 349.0475 416.2567 525.0390 600.4261 873.2222 1075.8287 1015.8822 
S23 P1 RT 0.0000 163.1324 515.2994 632.2024 598.7349 692.7218 756.9067 864.9798 896.0114 1083.9593 1140.0921 
S24 P2 TR 0.0000 215.6084 198.4274 251.9594 370.3540 366.0199 525.2591 623.2849 624.7862 925.1126 798.9364 
S25 P1 RT 0.0000 9.6337 178.8684 547.4662 354.3962 630.3674 660.8515 755.0630 695.7893 818.1053 829.7091 
S26 P2 TR 0.0000 0.0000 48.0348 82.0629 203.2466 334.9198 401.5256 622.6748 690.2441 723.4373 756.8766 
S27 P2 TR 0.0000 82.0230 132.8945 315.6964 524.1084 750.8146 720.3603 678.6648 777.1369 860.0975 649.3920 
S28 P1 RT 0.0000 107.9642 315.2834 372.4065 404.7512 530.2466 709.2109 926.3693 1006.2467 980.7263 930.1408 
S29 P2 TR 0.0000 12.0117 55.6291 101.6460 160.5904 331.2862 451.8679 711.1694 754.4205 756.8450 861.9112 
S31 P1 RT 0.0000 401.5277 465.1625 530.9713 439.9967 562.3867 701.4649 657.2774 679.8353 900.2588 766.6119 
S32 P2 TR 0.0000 M 145.3581 200.8866 302.3790 505.1046 496.9061 604.6178 626.9570 1026.4372 702.9541 
N 30 29 30 30 30 30 30 30 30 30 30
Mean 0.0000 76.3115 150.0579 235.7205 300.1932 417.9948 509.7250 596.6602 664.3496 803.8324 769.0242 
SD 0.0000 92.1200 116.6536 151.9885 145.0629 175.1657 187.4390 177.6951 193.6471 177.8827 160.1366 
Min 0.0000 0.0000 38.8141 40.8165 76.0894 88.0182 108.7450 118.1583 134.6661 276.6367 372.2172 
Median 0.0000 28.6770 117.4174 218.2583 289.4403 413.1383 504.7762 613.6463 653.3962 772.5607 761.7443 
Max 0.0000 401.5277 515.2994 632.2024 598.7349 761.6984 895.4255 926.3693 1006.2467 1083.9593 1140.0921 
CV% NC 120.7158 77.7390 64.4783 48.3232 41.9062 36.7726 29.7816 29.1484 22.1293 20.8233 
Geometric Mean NC NC 117.1980 189.5733 261.0645 376.1619 470.5376 561.7250 628.5215 780.7343 751.9330 
NC=Not Calculable, M=Missing 
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Table 6: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Reference Product (R) ………… (Contd) 
  Concentration (ng/mL) 
  Time (hr) Subject Period Sequence 
06.00 08.00 10.00 12.00 16.00 24.00 36.00 48.00 72.00 96.00 120.00 144.00 
S01 P1 RT 586.7722 593.7416 558.2968 546.4092 468.1742 449.4412 405.9600 300.0454 229.6364 150.6860 78.0071 58.9960 
S02 P2 TR 681.2346 645.2420 615.9841 604.8767 508.4187 516.0625 361.4457 260.6029 153.7312 76.3590 40.3426 22.8144 
S03 P1 RT 608.1647 567.6743 527.7008 545.7265 460.0049 442.9969 355.6084 242.2070 146.6745 113.6640 45.5425 31.7123 
S04 P2 TR 729.6131 687.1366 740.5875 769.9670 634.6268 618.2951 574.1783 464.0003 314.2460 224.1379 145.0400 93.8852 
S05 P2 TR 615.5550 585.9940 569.5508 521.9667 403.8515 438.6316 355.7193 256.1220 167.3021 92.5079 57.7607 36.2249 
S06 P1 RT 794.3800 743.2140 737.3856 683.1994 517.6004 589.1052 482.9579 398.1940 295.2162 159.9743 108.2227 68.1139 
S07 P1 RT 603.1941 657.8857 550.5377 490.6173 365.5846 375.7668 278.5743 194.2217 91.5927 54.0293 19.6897 0.0000 
S08 P2 TR 594.5199 460.0180 508.1895 353.8999 385.7755 317.8920 343.4151 158.3813 155.8259 101.6707 136.0766 36.3124 
S09 P2 TR 625.3840 612.9443 563.7039 577.3473 445.6039 407.0922 314.5717 197.4950 111.2855 57.1921 31.7658 18.5754 
S10 P1 RT 720.5821 688.4967 560.2339 610.3554 421.9672 418.4158 286.8229 206.8394 118.2621 59.5089 30.8631 13.2058 
S11 P1 RT 755.5040 626.4586 611.0972 587.8449 455.4034 455.5472 362.0774 311.9311 M 120.7537 90.5040 51.7849 
S12 P2 TR 535.1915 527.5999 532.9395 515.2967 378.5994 356.1156 M M 152.2030 67.9675 51.7436 27.2370 
S13 P1 RT 726.9908 648.4380 591.6569 511.5373 385.1993 386.2230 252.1357 160.3671 M 30.0166 M M 
S14 P2 TR 712.3834 646.1091 598.4914 603.2487 519.2462 449.8483 583.2171 250.3213 348.0840 216.1641 204.9454 152.4237 
S15 P1 RT 854.6599 751.2552 698.2999 759.4457 674.1867 681.5705 559.4560 418.5206 276.9030 187.1565 133.4199 83.8675 
S17 P2 TR 575.1907 749.1913 777.7613 789.4083 668.0560 708.9103 570.0556 479.6635 338.0569 228.8147 137.3909 100.1935 
S18 P1 RT 868.3628 828.6324 796.7134 733.4488 755.7443 794.4585 523.1307 509.6868 361.2482 251.0154 150.8218 106.2130 
S19 P1 RT 842.8140 757.3820 750.8929 757.6764 589.0068 587.9126 M M 311.6778 155.0590 71.9166 M 
S20 P2 TR 884.8672 897.8803 862.6888 798.0791 693.5190 674.7710 682.4603 457.3315 290.6565 181.2622 120.2592 86.6135 
S21 P1 RT 785.0568 677.8103 670.2500 684.7978 528.2519 606.9666 409.9171 328.2462 198.5952 128.0974 M M 
52
  Table 6: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Reference Product (R) ………… (Contd) 
  Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
06.00 08.00 10.00 12.00 16.00 24.00 36.00 48.00 72.00 96.00 120.00 144.00 
S22 P2 TR 1149.6729 917.2822 910.4406 868.9432 944.7254 757.1096 690.3876 605.1661 524.2901 452.1246 357.4192 202.0384 
S23 P1 RT 1027.6945 940.4231 946.3374 949.5692 748.1632 828.3968 732.5982 478.2380 317.9284 246.2211 109.4709 27.3993 
S24 P2 TR 803.6747 738.1582 732.2018 708.4489 585.1118 502.5547 444.6505 339.5311 177.3465 99.6263 52.9511 30.8017 
S25 P1 RT 637.3873 774.6127 496.4239 504.7183 430.8786 451.9184 287.4239 198.4740 88.3303 M M 13.7440 
S26 P2 TR 781.7848 687.9326 694.0101 577.7045 544.3094 542.9419 400.7323 236.1438 176.1613 28.3562 23.3639 19.0905 
S27 P2 TR 696.2695 688.8666 591.2237 581.3873 475.3304 448.0424 372.5831 228.5608 113.7459 67.9862 34.6206 21.3590 
S28 P1 RT 856.5734 799.6563 747.4095 854.3534 660.4005 536.4307 411.4325 304.8670 154.4661 80.5784 M 21.6955 
S29 P2 TR 715.8600 689.9496 771.2132 636.1203 559.7839 590.4697 387.5648 343.5523 184.5518 103.8609 62.3439 43.2195 
S31 P1 RT 777.1396 715.6679 809.6332 635.6304 536.0459 539.0189 333.3971 258.1589 109.8649 59.8626 36.4872 14.9804 
S32 P2 TR 885.4239 804.0708 817.5339 723.0739 670.7889 623.9527 529.5444 389.1481 348.9793 226.8655 168.1598 101.3519 
N 30 30 30 30 30 30 28 28 28 29 26 27 
Mean 747.7300 703.6575 677.9796 649.5033 547.1453 536.5620 439.0006 320.5720 223.4594 138.6731 96.1203 54.9575 
SD 138.1528 110.1955 125.2930 132.8153 136.2060 133.1226 132.8136 118.2363 107.2328 90.9258 73.8178 47.6113 
Min 535.1915 460.0180 496.4239 353.8999 365.5846 317.8920 252.1357 158.3813 88.3303 28.3562 19.6897 0.0000 
Median 728.3020 688.6817 682.1301 622.9929 523.7491 526.2466 403.3462 302.4562 180.9492 113.6640 74.9619 36.2249 
Max 1149.6729 940.4231 946.3374 949.5692 944.7254 828.3968 732.5982 605.1661 524.2901 452.1246 357.4192 202.0384 
CV% 18.4763 15.6604 18.4803 20.4488 24.8939 24.8103 30.2536 36.8829 47.9876 65.5684 76.7973 86.6330 
Geometric Mean 736.1203 695.2346 667.0146 636.1131 531.9715 521.0659 420.9022 300.5100 200.2565 113.6250 74.6635 NC 
 NC=Not Calculable, M=Missing 
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Table 7: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Test Product (T) 
   Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
00.00 00.25 00.50 00.75 01.00 01.50 02.00 02.50 03.00 04.00 05.00 
S01 P2 RT 0.0000 43.3406 151.5375 183.9230 274.9655 306.6002 409.9274 477.2791 566.1203 661.5518 617.2407 
S02 P1 TR 0.0000 45.3413 72.4236 162.0482 241.4220 352.6827 419.8404 456.1001 475.9830 648.2203 830.3812 
S03 P2 RT 0.0000 327.6114 407.9092 467.2177 518.3833 523.6288 632.8476 648.8888 698.7194 787.1794 569.9577 
S04 P1 TR 0.0000 39.2101 225.7612 324.6980 312.8713 465.9701 557.9967 738.8120 626.6330 814.5174 796.7807 
S05 P1 TR 0.0000 36.9045 111.5931 201.9784 237.6004 413.7769 490.4158 515.8897 586.0399 658.8675 636.9965 
S06 P2 RT 0.0000 72.8131 218.2346 336.4726 406.0354 448.0991 457.8720 542.6937 714.5665 661.3710 798.3499 
S07 P2 RT 0.0000 247.4942 452.8022 361.8574 333.6644 423.3197 470.8961 474.7661 583.2848 694.5733 612.1553 
S08 P1 TR 0.0000 178.0674 149.2245 193.8189 199.1886 280.4297 370.1235 661.8674 713.4776 691.1787 565.1883 
S09 P1 TR 0.0000 188.9042 184.2310 214.9091 271.1026 365.4929 440.8151 448.1925 567.1390 594.6142 670.9853 
S10 P2 RT 0.0000 73.2164 114.9691 155.9676 164.4904 350.0726 477.3590 543.4487 700.8296 712.0663 792.5082 
S11 P2 RT 0.0000 179.3185 178.8946 325.7758 355.5154 408.0355 539.7943 603.0335 665.8930 712.1718 708.7040 
S12 P1 TR 0.0000 151.1808 180.7985 269.2717 304.4113 449.6952 500.7856 560.3869 701.7693 654.1333 592.7438 
S13 P2 RT 0.0000 22.3382 175.4634 439.1873 464.9158 530.1180 612.1261 799.3957 896.7195 1003.6217 870.3289 
S14 P1 TR 0.0000 50.0422 159.5140 304.0323 300.7343 451.3508 521.2192 603.0374 703.5256 717.5147 783.6396 
S15 P2 RT 0.0000 79.0448 291.4829 337.5399 400.2118 500.7247 571.0489 662.4817 732.9119 942.3253 946.9818 
S17 P1 TR 0.0000 59.7386 326.2787 472.7285 570.0304 576.2559 680.1055 717.8819 751.8156 860.6010 881.5533 
S18 P2 RT 0.0000 36.9408 178.5573 194.3890 355.8201 388.6448 526.6547 741.8306 962.7772 1112.4377 881.9563 
S19 P2 RT 0.0000 108.3154 303.9433 398.6143 489.5564 508.3539 558.5124 711.3650 851.5196 1037.6480 906.7425 
S20 P1 TR 0.0000 0.0000 0.0000 112.6420 210.4587 320.2085 454.0248 551.9176 800.0866 835.7362 1021.9500 
S21 P2 RT 0.0000 191.5354 215.1128 383.9041 421.9661 507.4575 583.9137 737.5436 701.0023 790.4101 585.7276 
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Table 7: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Test Product (T) ………… (Contd) 
 Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
00.00 00.25 00.50 00.75 01.00 01.50 02.00 02.50 03.00 04.00 05.00 
S22 P1 TR 0.0000 24.4285 41.0672 194.6128 258.9891 416.4356 608.3675 755.8535 867.3997 993.9692 1043.3088 
S23 P2 RT 0.0000 127.4050 244.5804 278.1466 369.4580 402.6229 643.9728 759.4297 775.9478 1003.7225 1087.3276 
S24 P1 TR 0.0000 385.4698 345.2920 571.0513 578.8704 728.7722 827.3088 879.6360 843.2931 939.4123 921.0403 
S25 P2 RT 0.0000 0.0000 82.2098 127.5654 208.1953 374.4958 378.5859 467.4766 627.9835 761.1336 900.0824 
S26 P1 TR 0.0000 498.0869 398.2702 452.9894 497.4248 566.6656 699.1959 702.7883 707.4488 786.8731 688.9322 
S27 P1 TR 0.0000 194.9346 557.5513 554.5453 691.1304 710.0347 659.5843 779.3247 856.3887 855.0734 738.8795 
S28 P2 RT 0.0000 140.2160 261.8981 230.0554 290.8783 487.2773 552.6067 633.8479 760.8936 1011.5064 964.5760 
S29 P1 TR 0.0000 20.8229 119.3977 200.8651 315.4483 367.7002 500.1247 583.6504 621.9431 850.1370 860.4825 
S31 P2 RT 0.0000 74.5858 246.7300 464.6663 395.2416 696.2141 663.1204 846.3129 657.8550 908.0623 928.5160 
S32 P1 TR 0.0000 144.2717 283.3177 520.4269 431.6728 614.5262 684.2418 836.6752 818.6967 847.6750 940.2929 
N 30 30 30 30 30 30 30 30 30 30 30
Mean 0.0000 124.7193 222.6349 314.5300 362.3551 464.5221 549.7796 648.0602 717.9555 818.2768 804.8103 
SD 0.0000 117.7980 125.5279 133.5768 126.9664 116.7332 107.1577 126.4132 112.0096 139.6663 151.7412 
Min 0.0000 0.0000 0.0000 112.6420 164.4904 280.4297 370.1235 448.1925 475.9830 594.6142 565.1883 
Median 0.0000 76.8153 199.6719 314.3652 344.5899 448.8972 546.2005 655.3781 705.4872 802.4638 814.3656 
Max 0.0000 498.0869 557.5513 571.0513 691.1304 728.7722 827.3088 879.6360 962.7772 1112.4377 1087.3276 
CV% NC 94.4505 56.3829 42.4687 35.0392 25.1297 19.4910 19.5064 15.6012 17.0683 18.8543 
Geometric Mean NC NC NC 286.1901 341.6834 451.1601 539.8177 635.8432 709.3761 806.9553 790.4971 
NC=Not Calculable 
55
Table 7: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Test Product (T) ………… (Contd) 
        Concentration (ng/mL) 
                          Time (hr) Subject Period Sequence 
06.00 08.00 10.00 12.00 16.00 24.00 36.00 48.00 72.00 96.00 120.00 144.00 
S01 P2 RT 691.5759 812.0812 545.7473 524.6047 449.7609 487.7706 371.1852 298.0857 193.9889 144.1451 92.1234 53.7406 
S02 P1 TR 788.5166 718.0456 619.5282 647.6275 542.8373 501.6051 362.7632 267.4710 149.8872 98.5555 51.9421 32.6189 
S03 P2 RT 653.1599 656.1173 603.1861 586.3209 497.5262 476.7147 432.2614 298.2050 179.4146 134.6435 93.0129 66.9511 
S04 P1 TR 811.8905 736.7240 777.2833 685.5268 675.4288 754.1695 597.8947 498.5594 357.8196 277.0965 167.5461 99.6783 
S05 P1 TR 637.5306 574.0917 576.8831 583.9424 450.4366 441.8319 389.2902 276.3152 222.2946 125.9456 60.0624 35.9083 
S06 P2 RT 658.9468 647.5412 576.8712 554.5407 483.4382 522.6969 460.8402 448.2600 230.1736 149.5912 100.9213 72.2526 
S07 P2 RT 782.6899 850.3078 698.1424 660.8120 595.5466 556.2561 435.1233 261.7564 143.9685 69.7651 37.7705 12.9031 
S08 P1 TR 523.2538 734.5392 886.8234 639.0565 481.9045 556.9068 448.6881 356.8158 116.3618 63.0924 37.9943 19.6743 
S09 P1 TR 629.7778 623.3042 686.2809 559.7362 505.4521 387.6051 288.8008 206.9993 118.4716 69.4297 32.4594 26.6944 
S10 P2 RT 602.9519 596.7802 581.8085 567.6669 486.3650 456.5752 298.1240 188.6557 143.5428 67.2840 39.3819 19.1502 
S11 P2 RT 672.4355 630.4944 605.7067 559.5370 496.1653 504.4954 388.8740 279.3953 184.8565 113.3477 87.3769 51.7249 
S12 P1 TR 590.3046 477.7074 495.3927 471.8818 361.3221 378.1678 268.2028 274.5817 177.4558 96.5139 57.3880 37.6330 
S13 P2 RT 741.3575 509.4374 660.7733 587.8066 488.9371 431.4927 234.5785 165.3809 64.9972 28.9922 0.0000 0.0000 
S14 P1 TR 782.6232 632.2912 719.4948 693.0756 593.0592 576.0973 510.2070 439.0013 301.6217 232.3118 227.9634 219.5064 
S15 P2 RT 888.7488 853.5711 840.5985 759.3445 623.9342 661.8118 520.0959 422.6767 254.9946 152.5027 96.0039 68.2610 
S17 P1 TR 877.3714 806.4176 789.9520 769.9867 738.6568 703.9098 614.0404 454.9825 330.7047 253.4793 148.4803 97.3865 
S18 P2 RT 940.9542 881.1734 862.3606 668.1197 616.7434 640.1671 522.4238 446.5945 297.5966 181.8335 130.3545 70.8983 
S19 P2 RT 869.9400 796.1953 742.7764 720.1409 614.6505 624.9409 538.7249 332.7906 243.5959 159.9472 92.5653 53.9243 
S20 P1 TR 947.3449 799.0589 847.0843 715.7568 603.8162 733.7847 M M 320.5126 224.9888 137.3563 M 
S21 P2 RT 702.0179 677.9977 659.2648 647.1447 539.6727 494.4593 404.8050 286.2527 202.4219 108.9233 73.5491 42.8669 
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Table 7: Individual Subject plasma Lamotrigine Concentrations (ng/mL) for Test Product (T) ………… (Contd) 
  Concentration (ng/mL) 
Time (hr) Subject Period Sequence 
06.00 08.00 10.00 12.00 16.00 24.00 36.00 48.00 72.00 96.00 120.00 144.00 
S22 P1 TR 983.6242 923.3912 939.5418 925.2133 895.7744 876.5013 771.2606 695.4014 580.0574 435.1824 M M 
S23 P2 RT 1170.1828 1050.7534 1016.5133 1117.2163 932.3338 883.9973 616.3306 624.4692 475.1715 298.4778 195.1044 139.2704 
S24 P1 TR 840.3496 794.7307 712.0720 698.0321 518.7630 588.4065 497.2132 307.1329 176.0820 120.8769 58.0277 36.8374 
S25 P2 RT 770.0082 686.0833 689.6579 624.2284 451.1862 485.9651 315.4169 283.1021 99.3493 49.8547 29.6638 20.1901 
S26 P1 TR 530.8723 665.4680 648.8878 635.3195 507.2272 418.8603 369.4845 229.7312 139.3577 70.7758 30.0232 12.2660 
S27 P1 TR 725.0394 656.3708 610.8099 624.0856 493.0512 451.3715 366.7162 266.6128 130.3501 74.7562 39.9768 24.8356 
S28 P2 RT 924.8163 794.7485 823.1604 784.0736 569.6347 466.2106 410.5586 269.0333 129.4820 60.6541 34.9372 16.1103 
S29 P1 TR 812.3710 819.1004 804.5021 645.8845 538.9373 511.9603 432.6235 319.9352 125.5459 79.0559 43.1647 M 
S31 P2 RT 931.5878 861.7819 793.7934 766.1300 694.5569 578.3981 435.0264 290.1244 137.3027 76.7948 37.8597 15.5327 
S32 P1 TR 807.1777 846.4278 825.8647 785.5752 694.3017 760.0040 679.9390 453.0536 379.3749 263.0406 157.1931 140.0893 
N 30 30 30 30 30 30 29 29 30 30 29 27 
Mean 776.3140 737.0911 721.3587 673.6129 571.3807 563.7711 447.6377 342.8061 220.2251 142.7286 82.4208 55.0706 
SD 146.9332 127.6059 126.2781 126.2559 126.2884 135.4899 125.6859 123.7596 117.2020 92.3802 56.1272 49.1750 
Min 523.2538 477.7074 495.3927 471.8818 361.3221 378.1678 234.5785 165.3809 64.9972 28.9922 0.0000 0.0000 
Median 782.6566 735.6316 705.1072 647.3861 539.3050 517.3286 432.6235 298.0857 182.1356 117.1123 60.0624 37.6330 
Max 1170.1828 1050.7534 1016.5133 1117.2163 932.3338 883.9973 771.2606 695.4014 580.0574 435.1824 227.9634 219.5064 
CV% 18.9270 17.3121 17.5056 18.7431 22.1023 24.0328 28.0776 36.1019 53.2192 64.7244 68.0984 89.2946 
Geometric Mean 763.0077 726.1753 710.7889 663.5286 559.3858 549.3644 431.1089 323.9835 195.1578 118.6067 NC NC 
 NC=Not Calculable, M=Missing 
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Table 8: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine (Test Product -T)  
Test Product (T) 
Subject Sequence Cmax 
(ng/mL) 
AUC0-t 
(ng*hr /mL) 
AUC0-inf 
(ng*hr /mL) 
tmax 
(hr) 
Kel 
(hr)-1 
t½ 
(hr) 
S01 RT 812.0812 36115.3776 38743.3935 8.00 0.0204 33.8962 
S02 TR 830.3812 33249.8528 34687.0173 5.00 0.0227 30.5396 
S03 RT 787.1794 37504.8163 42197.9467 4.00 0.0143 48.5882 
S04 TR 814.5174 57506.0080 62198.4389 4.00 0.0212 32.6304 
S05 TR 658.8675 34453.1271 35846.6673 4.00 0.0258 26.8999 
S06 RT 798.3499 42361.2905 46775.4017 5.00 0.0164 42.3463 
S07 RT 850.3078 34510.6106 34935.3693 8.00 0.0304 22.8178 
S08 TR 886.8234 34121.3035 34931.9277 10.00 0.0243 28.5592 
S09 TR 686.2809 27393.7133 28507.6897 10.00 0.0240 28.9255 
S10 RT 792.5082 28573.2984 29276.0111 5.00 0.0273 25.4349 
S11 RT 712.1718 35790.5623 38590.2426 4.00 0.0185 37.5175 
S12 TR 701.7693 29363.7598 31128.1786 3.00 0.0213 32.4981 
S13 RT 1003.6217 24072.7977 24896.2493 4.00 0.0352 19.6871 
S14 TR 783.6396 53221.9294 75181.5522 5.02 0.0100 69.3431 
S15 RT 946.9818 47908.3624 51429.4955 5.00 0.0194 35.7549 
S17 TR 881.5533 56298.3055 62680.0901 5.00 0.0153 45.4223 
S18 RT 1112.4377 50895.0567 54877.9671 4.00 0.0178 38.9395 
S19 RT 1037.6480 45664.9808 47947.4694 4.00 0.0236 29.3393 
S20 TR 1021.9500 53154.5782 61222.7810 5.00 0.0170 40.7149 
S21 RT 790.4101 36695.0736 38827.8709 4.00 0.0201 34.4868 
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Table 8: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine (Test Product -
T) (contd…………)
Test Product (T) 
Subject Sequence Cmax 
(ng/mL) 
AUC0-t 
(ng*hr /mL) 
AUC0-inf 
(ng*hr /mL) 
tmax 
(hr) 
Kel 
(hr)-1 
t½ 
(hr) 
S22 TR 1043.3088 66973.6420 117166.2751 5.00 0.0087 79.9455
S23 RT 1170.1828 71363.7186 79536.8531 6.00 0.0170 40.6776
S24 TR 939.4123 40806.6000 42397.9544 4.00 0.0231 29.9436
S25 RT 900.0824 29758.1484 30496.2816 5.00 0.0274 25.3409
S26 TR 786.8731 31113.1712 31448.4140 4.00 0.0366 18.9444
S27 TR 856.3887 32334.8946 33348.5118 3.00 0.0245 28.2895
S28 RT 1011.5064 34109.0017 34667.2840 4.00 0.0289 24.0201
S29 TR 860.4825 34126.4347 36104.8419 5.00 0.0218 31.7697
S31 RT 931.5878 37332.5234 37874.4828 6.00 0.0287 24.1850
S32 TR 940.2929 59487.7134 69639.7591 5.00 0.0138 50.2313
N 30 30 30 30 30 30
Arithmetic Mean 878.3199 41208.6884 46252.0806 5.10 0.0219 35.2563 
Standard Deviation 126.7126 12251.5909 19741.5045 1.75 0.0066 13.4131 
Minimum 658.8675 24072.7977 24896.2493 3.00 0.0087 18.9444
Median 858.4356 36405.2256 38666.8181 5.00 0.0216 32.1339
Maximum 1170.1828 71363.7186 117166.2751 10.00 0.0366 79.9455
CV (%) 14.4267 29.7306 42.6824 34.29 30.1544 38.0446 
Geometric Mean 869.6279 39619.8622 43173.8702 4.87 0.0208 33.3122 
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Table 8: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine (Test Product -
T) (contd………)
Test Product (T) 
Subject Sequence 
AUC_Extrap (%) Kel_Lower (hr) Kel_Upper (hr) 
S01 RT 6.78 96.22 144.50
S02 TR 4.14 8.00 143.13
S03 RT 11.12 74.05 144.27
S04 TR 7.54 95.75 143.87
S05 TR 3.89 71.53 143.80
S06 RT 9.44 72.50 143.70
S07 RT 1.22 24.00 144.32
S08 TR 2.32 71.60 143.92
S09 TR 3.91 12.00 143.92
S10 RT 2.40 71.77 144.37
S11 RT 7.25 4.00 144.87
S12 TR 5.67 48.48 144.12
S13 RT 3.31 36.43 96.80
S14 TR 29.21 5.02 143.67
S15 RT 6.85 24.00 144.37
S17 TR 10.18 5.00 144.23
S18 RT 7.26 24.00 144.68
S19 RT 4.76 97.55 143.57
S20 TR 13.18 24.00 120.68
S21 RT 5.49 6.00 143.83
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Table 8: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine (Test Product -
T) (contd………)
Test Product (T) 
Subject Sequence 
AUC_Extrap (%) Kel_Lower (hr) Kel_Upper (hr) 
S22 TR 42.84 10.00 96.67
S23 RT 10.28 72.33 144.60
S24 TR 3.75 24.00 145.58
S25 RT 2.42 6.00 144.30
S26 TR 1.07 97.67 145.57
S27 TR 3.04 5.00 144.73
S28 RT 1.61 4.00 144.83
S29 TR 5.48 71.38 120.35
S31 RT 1.43 6.00 145.37
S32 TR 14.58 5.00 143.32
N 30 30 30
Arithmetic Mean 7.75 39.11 139.53 
Standard Deviation 8.65 34.82 13.11 
Minimum 1.07 4.00 96.67
Median 5.49 24.00 144.18
Maximum 42.84 97.67 145.58
CV (%) 111.72 89.03 9.40 
Geometric Mean 5.24 22.25 138.81 
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Table 9: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine 
(Reference Product -R)  
Reference Product (R) 
Subject Sequence Cmax 
(ng/mL) 
AUC0-t 
(ng*hr /mL) 
AUC0-inf 
(ng*hr /mL) 
tmax 
(hr) 
Kel 
(hr)-1 
t½ 
(hr) 
S01 RT 633.1102 36195.0890 39701.8545 4.00 0.0168 41.2012
S02 TR 728.2911 31970.0258 32852.7001 5.00 0.0258 26.8174
S03 RT 666.2595 30927.0913 32408.5412 4.00 0.0214 32.3806
S04 TR 911.9164 52571.5502 57757.5128 4.00 0.0181 38.2876
S05 TR 631.3911 30880.2038 32714.8000 4.00 0.0197 35.1042
S06 RT 799.5141 44690.3121 48514.5453 5.00 0.0178 38.9165
S07 RT 657.8857 23314.8001 23976.1187 8.00 0.0298 23.2808
S08 TR 1068.7052 30240.7050 32421.9814 4.00 0.0166 41.6372
S09 TR 741.9582 26894.0808 27697.8561 4.00 0.0231 29.9931
S10 RT 733.5562 26630.6338 27105.1957 5.00 0.0278 24.9088
S11 RT 788.4956 36470.5339 39373.4096 5.00 0.0178 38.8553
S12 TR 706.2136 28156.7668 29428.9718 3.00 0.0214 32.3760
S13 RT 839.2519 23059.8256 23915.2845 4.00 0.0351 19.7544
S14 TR 725.2247 47738.3215 61977.7877 4.00 0.0107 64.7540
S15 RT 934.6100 49850.4950 54903.6285 5.02 0.0166 41.7631
S17 TR 789.4083 51971.2210 58080.5863 12.00 0.0164 42.2651
S18 RT 953.8982 57020.8079 63370.8003 5.00 0.0167 41.4401
S19 RT 980.9137 46324.9030 48696.5284 4.00 0.0303 22.8582
S20 TR 1050.2917 54436.6970 59532.9962 4.00 0.0170 40.7845
S21 RT 883.1366 34799.8973 41538.5059 5.00 0.0190 36.4633
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Table 9: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine 
(Reference Product -R) (Contd………) 
Reference Product (R) 
Subject Sequence Cmax 
(ng/mL) 
AUC0-t 
(ng*hr /mL) 
AUC0-inf 
(ng*hr /mL) 
tmax 
(hr) 
Kel 
(hr)-1 
t½ 
(hr) 
S22 TR 1149.6729 78614.9358 99251.5238 6.00 0.0098 70.7994
S23 RT 1140.0921 60538.1342 61137.6709 5.00 0.0457 15.1671
S24 TR 925.1126 37869.0130 39113.7060 4.00 0.0247 28.0100
S25 RT 829.7091 27423.7735 27918.4051 5.00 0.0278 24.9456
S26 TR 781.7848 31897.7636 34223.2373 5.98 0.0082 84.4344
S27 TR 860.0975 30285.9196 31201.6374 4.00 0.0233 29.7171
S28 RT 1006.2467 37901.5774 38703.1228 3.00 0.0271 25.6085
S29 TR 861.9112 37880.2634 39914.8532 5.00 0.0212 32.6304
S31 RT 900.2588 32041.0474 32569.8834 4.00 0.0283 24.4694
S32 TR 1026.4372 52621.0635 59592.0038 4.00 0.0145 47.6744
N 30 30 30 30 30 30
Arithmetic Mean 856.8452 39707.2484 43319.8550 4.80 0.0216 36.5766 
Standard Deviation 146.3876 13022.9511 16520.9636 1.67 0.0078 14.9673 
Minimum 631.3911 23059.8256 23915.2845 3.00 0.0082 15.1671
Median 849.6747 36332.8115 39243.5578 4.00 0.0205 33.8673
Maximum 1149.6729 78614.9358 99251.5238 12.00 0.0457 84.4344
CV (%) 17.0845 32.7974 38.1372 34.77 36.1960 40.9204 
Geometric Mean 844.8876 37863.1982 40744.7497 4.61 0.0203 34.1400 
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Table 9: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine 
(Reference Product -R) (Contd………) 
Reference Product (R) 
Subject Sequence 
AUC_Extrap (%) Kel_Lower (hr) Kel_Upper (hr) 
S01 RT 8.83 4.00 143.12
S02 TR 2.69 24.00 144.22
S03 RT 4.57 4.00 143.17
S04 TR 8.98 96.50 144.55
S05 TR 5.61 96.75 144.23
S06 RT 7.88 95.80 143.73
S07 RT 2.76 24.00 120.13
S08 TR 6.73 5.00 144.10
S09 TR 2.90 95.60 144.27
S10 RT 1.75 24.00 143.95
S11 RT 7.37 24.00 144.33
S12 TR 4.32 6.00 144.67
S13 RT 3.58 35.47 96.03
S14 TR 22.98 4.00 145.20
S15 RT 9.20 48.32 143.60
S17 TR 10.52 24.00 143.83
S18 RT 10.02 48.58 144.15
S19 RT 4.87 72.35 120.67
S20 TR 8.56 71.90 143.55
S21 RT 16.22 35.00 96.73
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Table 9: Comparative Evaluation of Pharmacokinetic Parameters for lamotrigine 
(Reference Product -R) (Contd………) 
Reference Product (R) 
Subject Sequence 
AUC_Extrap (%) Kel_Lower (hr) Kel_Upper (hr) 
S22 TR 20.79 8.00 143.90
S23 RT 0.98 97.58 145.58
S24 TR 3.18 35.82 144.63
S25 RT 1.77 35.40 144.52
S26 TR 6.80 96.28 144.47
S27 TR 2.93 72.07 144.98
S28 RT 2.07 35.43 144.62
S29 TR 5.10 6.00 144.20
S31 RT 1.62 4.00 143.75
S32 TR 11.70 6.00 144.17
N 30 30 30
Arithmetic Mean 6.91 41.20 139.44 
Standard Deviation 5.42 34.53 13.17 
Minimum 0.98 4.00 96.03
Median 5.35 35.20 144.16
Maximum 22.98 97.58 145.58
CV (%) 78.50 83.82 9.45 
Geometric Mean 5.21 24.82 138.71 
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Table 10: Summary of Pharmacokinetic Parameters of Test Product-T and Reference Product –R
Untransformed Data (Mean ± SD) PK Parameter N 
Test Product (T) Reference product (R) 
Cmax (ng/mL) 30 878.3199 ± 126.7126 856.8452 ±   146.3876 
AUC0-t (ng.hr/mL) 30 41208.6602 ± 12251.5548 39707.4398 ±  13022.8598 
AUC0-∞ (ng.hr/mL) 30 46252.0556 ±  19741.4433 43320.0612 ± 16520.8670 
*tmax (hr) 30 4.98 (3.00-10.00) 4.00 (3.00-12.00) 
Kel (hr-1) 30 0.021 ± 0.9 0066 0.021 ± 0.006 78 
t1/2 (hr) 30 35.2564 ± 13.4131 36.576 ± 14.9 9671 
Kel_Lower (hr) 30 39.1053 ±  34.8231 41.190 ± 34.3 5327 
Kel_upper (hr) 30 139.528 ± 0 13.1087 139.4313 ± 13 .1749 
AUC_%Extrap_obs (%) 30 7.7471 ±  8.6547 6.909 ± 5.427 38 
* Expressed in terms of median (range)
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Pharmacokinetic Linear and Semi-logarithmic scattered Plots of Individual Plasma Concentration vs. Time for lamotrigine 
by treatment (N=30) 
Figure 2
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Figure 3 
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Figure 4 
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Figure 5 
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Pharmacokinetic Linear and Semi-logarithmic Plots of Mean Plasma Concentration vs Time for lamotrigine (N=30)  
Figure 6
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Figure 7 
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Statistical Analysis 
The individual pharmacokinetic parameters for each subject according to treatment are 
given in table 8 and table 9.  For Lamotrigine, analysis of variance (ANOVA) was 
performed on the Ln-transformed data of Cmax, AUC0-t and AUC0-∞ using mixed 
procedure of SAS® (version 9.2) software. The analysis of variance model included 
sequence, period and treatment as fixed effect and the subjects nested within the 
sequence as the error term at 5% level of the significance. For all analysis, effects were 
considered statistically significant if the probability (p-value) associated with ‘F’ was 
less than 0.05. Based on comparisons of the test and reference product for Ln-
transformed Cmax, AUC0-t and AUC0-∞ data, the ratio of the least square mean was 
calculated, as well as the 90% confidence intervals for Ln-transformed Cmax, AUC0-t 
and AUC0-∞ and also the intra-subject CV % was determined. 
Peak or maximal plasma concentration (Cmax):  
This parameter was calculated for each subject with respect to treatment and the 
results are presented in mean values (± SD) of Cmax for test product (T) was 878.3199 
± 126.7126 ng/mL and for reference product (R) was 856.8452 ± 146.3876 ng.hr/mL.  
Area under the concentration-time curve from time zero to t (AUC0-t):  
This parameter was calculated for each subject with respect to treatment and the 
results are presented in mean values (± SD) of AUC0-t for test product (T) was 
41208.6602 ± 12251.5548 ng.hr/mL and for reference product (R) was 39707.4398 ± 
13022.8598 ng.hr/mL.
Area under the concentration-time curve from time zero to infinity (AUC0-∞):  
This parameter was calculated for each subject with respect to treatment and the 
results are presented in mean values (±SD) for AUC0-∞ for test product (T) was 
46252.0556 ± 19741.4433 ng.hr/mL and for reference product (R) was 43320.0612 ± 
16520.8670 ng.hr/mL. 
The ANOVA was performed on the Ln-transformed Cmax, AUC0-t and AUC0-∞ 
parameters. The least-square mean ratio, the 90% confidence intervals and intra-
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subjects CVs were also determined for Cmax, AUC0-t and AUC0-∞.  These results are 
summarized in the following Table 11. 
Statistical / Analytical Issues 
There were no statistical/analytical issues observed in the study. 
Adjustments of Covariates 
No adjustment for covariates was made.  
Pharmacokinetic Conclusions 
Based on the results obtained, Lamotrigine tablets 50 mg manufactured by Edict 
Pharmaceuticals, Chennai, India and LAMICTAL® ODT™ orally disintegrating 
tablets 50 mg tablets, manufactured by GlaxoSmithKline, Research Triangle Park, 
NC 27709  following a single dose of 50 mg are found to be bioequivalent in healthy, 
adult, human subjects under fed conditions. 
6.2 SAFETY EVALUATION 
Extent of Exposure 
Subjects were administered a single oral dose of Lamotrigine 50 mg tablet [test or 
reference, as per randomization schedule on two occasions with a washout period of 
14 days between dosing of each period. All the 30 subjects were exposed to both test 
and reference treatments. 
Table 11:  Statistical Results of Test Product-T versus Reference Product-R for Lamotrigine 
Anti Log of Least 
Square Mean PK Parameter Test Product 
(T) 
Reference Product 
(R) 
(T/R) 
Ratio % 
90% 
Confidence 
Intervals 
Intra subject 
CV 
(%) 
Cmax (ng/mL) 869.6279 844.8876 102.93 % 99.78 % to 106.17 % 7.07 % 
AUC0-t 
(ng.hr/mL) 39619.839 37863.430 104.64 % 101.11 % to 108.29 % 7.83 % 
AUC0-∞
(ng.hr/mL) 43173.858 40745.005 105.96 % 102.05 % to 110.03 % 8.59 % 
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Adverse Events (AE’s) 
Brief Summary of Adverse Events  
The details of the AEs including the name of the event, intensity, onset and resolution 
date, outcome, relation to the study product and action taken to manage the events 
are presented in table 12.
Analysis of Adverse Events 
During the conduct of the study, there were totally two adverse events noted. Both the 
adverse events were mild and there was a possibility of the adverse event being 
related to the drug in S02. Subject no. S02 reported adverse event of Nausea after 
dosing of the test product in period I and the adverse event was resolved without any 
sequelae on the same day and the subject was not withdrawn from the study. S03 
reported adverse event of  Fever and Loss of appetite after dosing of the test product 
in period II and the subject was treated with Combiflam (Ibuprofen + Paracetamol) 
400mg+500mg (one tablet) and the adverse event was resolved without any sequelae 
on the next day and the possibility of the adverse event being related to the drug is 
None/Doubtful. The above said subjects were not withdrawn from the study. There 
were no adverse events recorded during post study evaluation. 
Deaths, Other Serious Adverse Events, and other Significant Adverse Events 
There were no deaths, SAE or significant adverse events noted in this study. 
Safety Conclusions 
The incidence of adverse event reported after administration of test and reference 
products were given in table 12. Safety was evaluated from screening till 
completion of study through clinical examination, lab evaluation and vital sign 
assessment. Two adverse events were reported during in-house confinement. There 
were no adverse events reported during post study evaluation. There were no serious 
adverse event(s) reported during the study.  Thus it can be reasonably concluded that 
both the test and reference products were comparable at the selected dose level. 
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Table 12: Adverse events 
Test Product (T): Lamotrigine tablets 50 mg manufactured by Edict Pharmaceuticals, Chennai, India. 
Reference Product (R):  LAMICTAL® ODTTM (Lamotrigine) Orally Disintegrating Tablets 50 mg of 
GlaxoSmithKline,Research Triangle Park, NC2770Listing of Deaths, other Serious and Significant Adverse 
Events 
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Description 
Subject 
No. 
Name of 
the 
Event 
Treatment
Pre-
study 
value 
Post-
study 
value 
Onset 
Date
Resolution 
Date
Action TakenSeverity Outcome 
Relationship to 
study Products
S02 Nausea T N/AP 20 Dec 13 N/AP Nil Mild Resolved Possible 
S03 
Fever, 
Loss of 
appetite 
T N/AP N/AP
Treated with 
one tablet of 
Combiflam 
(Ibuprofen 
and 
Paracetamol, 
400 mg + 
500 mg) 
Mild Resolved None/Doubtful  08 Jan 14 09 Jan 14
21 Dec 13
77
7. DISCUSSION
The main objectives of this study was to evaluate the relative bioavailability of 
Lamotrigine of Edict Pharmaceuticals with that LAMICTAL® ODT™ (Lamotrigine) 
orally disintegrating tablets 50 mg of GlaxoSmithKline, Research Triangle Park, 
NC27709   in 32 healthy, human, adult subjects under fed conditions and to monitor 
the safety of subjects. 
32 subjects in the age group of 18 to 42 years who met the eligibility criteria were 
enrolled into the study and all the enrolled subjects were completed the study, except 
S16 and S30. The study was conducted over a period of 22days with a washout 
period of 14 days. Vital signs were comparable throughout the study.  Only S16 and 
S30 reported mild adverse event during the course of the study, but resolved without 
any sequelae. Thus it can be reasonably concluded that the investigational products 
were safe and well tolerated at the selected dose level in the human subjects.  
The pharmacokinetic and statistical analyses were performed on data from 30 
subjects. The results of the pharmacokinetic analysis of Lamotrigine with the test 
product were comparable to the reference product. Analysis of variance for Ln-
transformed pharmacokinetic parameters revealed that there was no significant effect 
of variation due to sequence for all the primary pharmacokinetic parameters with the 
p-values 0.6084, 0.4531 and 0.3321 for Cmax, AUC0-t and AUC0-. Cmax is significant 
for period with the p-value 0.0243 and insignificant for treatment with the p-value 
0.1247. AUC0-t is significant for treatment and insignificant for period with the p-
values 0.0327 and 0.6889. AUC0-∞ is significant for treatment and insignificant for 
period with the p-values 0.0142 and 0.7834 respectively. 
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8. CONCLUSION
The main objective of bioequivalence studies is to assure the efficacy and safety of 
generic formulations. Therefore, two formulations of the same drug are considered to 
be bioequivalent and ergo therapeutically equivalent if they exhibit a comparable extent 
and rate of absorption, when they are administered in the same molar dose and under 
similar experimental conditions. The study procedure was followed as per the GCP, 
ICMR, and Ethics committee guidelines to ensure the wellbeing of the study subjects. 
The duration of the study was followed as 22 days with the wash out period of 14 days 
to compare the reference and test products of Lamotrigine 20 mg tablets.
The 90% confidence interval of the least square mean of Cmax, AUC0-t and AUC0-∞  
were    (99.78 % to 106.17 %), (101.11 % to 108.29 %) and (102.05 % to 110.03 %), 
respectively, within the limit of 80.00 % and 125.00 %. Two adverse events were 
reported during in-house confinement for the test product. There were no adverse 
events reported during post study evaluation and no serious adverse events) reported 
during the study. It can be reasonably concluded that both the test and reference 
products were comparable for safety at the selected dose level.
Based on the results obtained in this study, test product Lamotrigine Orally 
Disintegrating 50 mg Tablets and reference product LAMICTAL® ODTTM 
(Lamotrigine) Orally Disintegrating 50 mg Tablets are found to be bioequivalent and 
well tolearated in healthy, adult, human subjects under fed conditions.
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